WO2006020768A2 - Chemically modified oligonucleotides - Google Patents
Chemically modified oligonucleotides Download PDFInfo
- Publication number
- WO2006020768A2 WO2006020768A2 PCT/US2005/028550 US2005028550W WO2006020768A2 WO 2006020768 A2 WO2006020768 A2 WO 2006020768A2 US 2005028550 W US2005028550 W US 2005028550W WO 2006020768 A2 WO2006020768 A2 WO 2006020768A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- ligand
- oligonucleotide
- agent
- group
- Prior art date
Links
- 0 CC1=C2C*CC1CCC2 Chemical compound CC1=C2C*CC1CCC2 0.000 description 26
- IOIWVDAAJJDPKL-FAJXHAIOSA-N CC(C1)(C1(C)N(C(c1ccccc11)=O)C1=O)C(NC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1)=O)C1=O)=O Chemical compound CC(C1)(C1(C)N(C(c1ccccc11)=O)C1=O)C(NC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1)=O)C1=O)=O IOIWVDAAJJDPKL-FAJXHAIOSA-N 0.000 description 1
- YVSGXMATHIIWAN-UHMNONSZSA-N CC1(C)OC2[C@H](N(C=CC(N3)=O)C3=O)O[C@H](CN)C2O1 Chemical compound CC1(C)OC2[C@H](N(C=CC(N3)=O)C3=O)O[C@H](CN)C2O1 YVSGXMATHIIWAN-UHMNONSZSA-N 0.000 description 1
- UNEYGWCXYCXEJI-WFXDJJTDSA-N CNC(NC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1)=O)C1=O)=O Chemical compound CNC(NC[C@H](C(C1O)O)O[C@H]1N(C=CC(N1)=O)C1=O)=O UNEYGWCXYCXEJI-WFXDJJTDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Definitions
- This invention relates generally to chemically modified oligonucleotides useful for modulating gene expression. More particularly, the invention relates to single stranded chemically modified oligonucleotides for inhibiting gene expression and to methods of making and using the modified oligonucleotides.
- nucleic acid species are capable of modifying gene expression. These include antisense RNA, siRNA, microRNA, RNA and DNA aptamers, and decoy RNAs. Each of these nucleic acid species can inhibit gene expression by a different mechanism.
- the invention features methods and compositions for modulating, either inhibiting or up- regulating, gene expression by using a conjugate of an oligonucleotide agent (a term which is defined below) and a ligand.
- the compositions include conjugated oligonucleotide agents as well as conjugated monomers that are the components of or can be used to make the conjugated oligonucleotide agents.
- the conjugated oligonucleotide agents can modify gene expression by targeting and binding to a nucleic acid, e.g., a pre-mRNA, an mRNA, a microRNA (miRNA), a mi-RNA precursor (pre-miRNA), or DNA, or to a protein.
- An oligonucleotide agent featured in the invention can be, e.g., an miRNA, antisense RNA, decoy RNA, DNA, or aptamer.
- the invention features an oligonucleotide agent coupled to a ligand.
- the ligand can be attached to the oligonucleotide agent through a monomer, e.g., a chemically modified monomer that is integrated into the oligonucleotide agent.
- the coupling is by a tether or a linker (or both) as described herein, and the complex has the formula represented by: Ligand- [linker] op tionai -[tether] op ti O nai - oligonucleotide agent
- oligonucleotide agent including a number of nucleotides
- the invention includes monomelic subunits having the structure:
- the sugar e.g., the ribose sugar of one or more of the nucleotides, (e.g., ribonucleotide, deoxynucleotide, or modified nucleotide) subunits of an oligonucleotide agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier.
- a nucleotide subunit in which the sugar of the subunit has been so replaced is referred to herein as a sugar replacement modification subunit (SRMS).
- SRMS sugar replacement modification subunit
- a cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, or sulfur.
- the cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings.
- the cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.
- the carriers further include (i) at least two "backbone attachment points” and (ii) at least one "tethering attachment point.”
- a "backbone attachment point” as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid.
- a "tethering attachment point" as used herein refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety.
- the moiety can be, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property.
- One of the most preferred moieties is a moiety which promotes entry into a cell, e.g., a lipophilic moiety, e.g., cholesterol.
- the attachment of a lipophilic agent increases the lipophilicity of an oligonucleotide agent.
- the selected moiety is connected by an intervening tether to the cyclic carrier.
- it will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.
- incorporación of one or more SRMSs described herein into an oligonucleotide agent can confer one or mpre new properties to the oligonucleotide agent and/or alter, enhance or modulate one or more existing properties in the oligonucleotide agent. E.g., it can alter one or more of lipophilicity or nuclease resistance.
- Incorporation of one or more SRMSs described herein into an oligonucleotide agent can, particularly when the SRMS is tethered to an appropriate entity, modulate, e.g., increase, binding affinity of an oligonucleotide agent to a target RNA, e.g., a pre-mRNA, mRNA, or miRNA of the subject or a pathogen of the subject.
- Incorporation of one or more SRMSs can alter distribution, target the oligonucleotide agent to a particular part of the body, modify the interaction with nucleic acid binding proteins (e.g., during RISC formation and strand separation), or increase sequence specificity, e.g, to inhibit off-site targeting.
- an oligonucleotide agent preferably comprising at least one subunit having the structure of formula (I) :
- X is N(CO)R 7 , NR 7 or CH 2 ;
- Y is NR 8 , O, S, CR 9 R 10 , or absent;
- R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a , or (CH 2 ) n OR b (when the SRMS is terminal, one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 will include R a and one will include R b ; when the SRMSS is internal, two of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 will each include an R b ;
- R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with
- R 7 can be a ligand, e.g., R 7 can be R d , or R 7 can be a ligand tethered indirectly to the carrier, e.g., through a tethering moiety, e.g., C 1 -C 20 alkyl substituted withNR c R d ; or C 1 -C 20 alkyl substituted with NHC(O)R d ;
- R 8 is C 1 -C 6 alkyl
- R 13 is hydroxy, C 1 -C 4 alkoxy, or halo
- R 14 is NR 0 R 7 ;
- R a is:
- R b is:
- a and C is, independently, O or S; B is OH, O " , or
- R c is H or C 1 -C 6 alkyl
- R d is H or a ligand, e.g., a lipophilic ligand, e.g., cholesterol; and n is 1-4.
- R 1 can be CH 2 OR 3 and R 3 can be OR b ; or R 1 can be CH 2 0R a and R 9 can be 0R b ; or R 1 can be CH 2 0R a and R 2 can be OR b .
- R 1 can be CH 2 OR b and R 3 can be OR b ; or R 1 can be CH 2 0R b and R 9 can be OR b ; or R 1 can be CH 2 0R b and R 2 can be OR b ; or R 1 can be CH 2 OR b and R 3 can be OR a ; or R 1 can be CH 2 0R b and R 9 can be OR a ; or R 1 can be CH 2 0R b and R 2 can be OR a .
- R 1 can be OR a and R 3 can be CH 2 0R b ; or R 1 can be OR a and R 9 can be CH 2 0R b ; or R 1 can be OR a and R 2 can be CH 2 OR b .
- R 1 can be OR b and R 3 can be CH 2 0R b ; or R 1 can be OR b and R 9 can be CH 2 0R b ; or R 1 can be OR b and R 2 can be CH 2 OR b ; or R 1 can be OR b and R 3 can be CH 2 OR 3 ; or R 1 can be OR b and R 9 can be CH 2 OR 3 ; or R 1 can be OR b and R 2 can be CH 2 OR 3 .
- R 3 can be CH 2 OR 3 and R 9 can be OR b ; or R 3 can be CH 2 OR 3 and R 4 can be OR b .
- R 3 can be CH 2 OR b and R 9 can be OR b ; or R 3 can be CH 2 OR b and R 4 can be 0R b ; or R 3 can be CH 2 OR b and R 9 can be OR a ; or R 3 can be CH 2 OR b and R 4 can be OR a .
- R 3 can be OR b and R 9 can be CH 2 OR 3 ; or R 3 can be OR b and R 4 can be CH 2 OR 3 ; or R 3 can be OR b and R 9 can be CH 2 OR b ; or R 3 can be OR b and R 4 can be CH 2 OR b .
- R 3 can be OR 3 and R 9 can be CH 2 OR b ; or R 3 can be OR 3 and R 4 can be CH 2 OR b .
- R 9 can be CH 2 OR a and R 10 can be OR b .
- R 9 can be CH 2 OR b and R 10 can be OR b ; or R 9 can be CH 2 0R b and R 10 can be OR a .
- the ribose is replaced with a pyrroline scaffold or with a 4- hydroxyproline-derived scaffold, and X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.
- R 1 and R 3 can be cis or R 1 and R 3 can be trans.
- n can be 1.
- A can be O or S.
- R 1 can be (CH 2 ) n OR b and R 3 can be OR b ; or R 1 can be (CH 2 ) n OR a and R 3 can be OR b .
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be chosen from a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- R 1 can be OR b and R 3 can be (CH 2 ) n OR b ; or R 1 can be OR b and R 3 can be (CH 2 ) n OR a ; or R 1 can be OR a and R 3 can be (CH 2 ) n OR b ; or R 1 can be (CH 2 ) n OR b and R 9 can be OR a .
- R 1 and R 9 can be cis or R 1 and R 9 can be trans.
- R 1 can be OR a and R 9 can be(CH 2 ) n OR b ; or R 1 can be (CH 2 ) n OR b and R 9 can be OR b ; or R 1 can be (CH 2 ) n OR a and R 9 can be OR b ; or R 1 can be OR b and R 9 can be (CH 2 ) n OR b ; or R 1 can be OR b and R 9 can be(CH 2 ) n OR a .
- R 3 can be (CH 2 ) n OR b and R 9 can be OR a ; or R 3 can be (CH 2 ) n OR b and R 9 can be OR b ; or R 3 can be (CH 2 ) n OR a and R 9 can be OR b ; or R 3 can be OR a and R 9 can be(CH 2 ) n OR b ; R 3 can be OR b and R 9 can be(CH 2 ) n OR b ; or R 3 can be OR b and R 9 can be(CH 2 ) n OR a .
- R 3 and R 9 can be cis or R 3 and R 9 can be trans.
- the ribose is replaced with a piperidine scaffold, and X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is CR 11 R 12 .
- R 9 can be (CH 2 ) n OR b and R 10 can be OR ⁇ n can be 1 or 2.
- R 9 can be (CH 2 ) n OR b and R 10 can be OR b ; or
- R 9 can be (CH 2 ) n OR a and R 10 can be OR b .
- A can be O or S.
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be selected from a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- R 3 can be (CH 2 ) n OR b and R 4 can be OR a ; or R 3 can be (CH 2 ) n OR b and R 4 can be OR b ; or
- R 3 can be (CH 2 ) n OR a and R 4 can be OR b .
- R 1 can be (CH 2 ) n OR b and R 2 can be OR a ; or R 1 can be (CH 2 ) n OR b and R 2 can be OR b ; or R 1 can be (CH 2 ) n OR a and R 2 can be OR b .
- R 3 can be (CH 2 ) n OR b and R 9 can be OR a .
- R 3 and R 9 can be cis, or R 3 and R 9 can be trans.
- R 3 can be (CH 2 ) n OR b and R 9 can be OR b ; or
- R 3 can be (CH 2 ) n OR b and R 9 can be OR a ; or
- R 3 can be (CH 2 ) n OR a and R 9 can be OR b .
- R 1 can be (CH 2 ) n OR b and R 3 can be OR a .
- R 1 and R 3 can be cis, or R 1 and R 3 can be trans.
- R 3 can be OR a and R 9 can be (CH 2 ) n OR b .
- R 1 can be OR a and R 3 can be (CH 2 ) n OR b .
- the ribose is replaced with a piperazine scaffold, and X is N(CO)R 7 or NR 7 , Y is NR 8 , and Z is CR 11 R 12 .
- R 1 can be (CH 2 ) n OR b and R 3 can be OR a .
- R 1 and R 3 can be cis or R 1 and R 3 can be trans.
- n canbe l.
- R 1 can be (CH 2 ) n OR b and R 3 can be OR b ; or R 1 can be (CH 2 ) n OR a and R 3 can be OR b .
- A can be O or S, preferably S.
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be chosen from the group of a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- R 8 can be CH 3 .
- R 1 can be OR a and R 3 can be (CH 2 ) n OR b .
- the ribose is replaced with a morpholino scaffold, and X is N(CO)R 7 or NR 7 , Y is O, and Z is CR 11 R 12 .
- R 1 can be (CH 2 ) n OR b and R 3 can be OR a .
- R and R can be cis, or R and R can be trans.
- n can be 1.
- R 1 can be (CH 2 ) n OR b and R 3 can be OR b ; of R 1 can be (CH 2 ) n OR a and R 3 can be OR b .
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be chosen from the group of a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- R 8 can be CH 3 .
- R 1 can be OR a and R 3 can be (CH 2 ) n OR b .
- the ribose is replaced with a decalin scaffold, and X isCH 2 ; Y is CR 9 R 10 ; and Z is CR 11 R 12 ; and R 5 and R 11 together are C 6 cycloalkyl.
- R 6 can be C(O)NHR 7 .
- R 12 can be hydrogen.
- R 6 and R 12 can be trans.
- R 3 can be OR a and R 9 can be (CH 2 ) n OR b .
- R 3 and R 9 can be cis, or R 3 and R 9 can be trans.
- n can be 1 or 2.
- R 3 can be OR b and R 9 can be (CH 2 ) n OR b ; or R 3 can be OR b and R 9 can be (CH 2 ) n OR a .
- A can be O or S.
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be chosen from the group of a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- the ribose is replaced with a decalin/indane scaffold, e.g., X is CH 2 ; Y is CR 9 R 10 ; and Z is CR 11 R 12 ; and R 5 and R 11 together are C 5 cycloalkyl.
- R 6 can be CH 3 .
- R 12 can be hydrogen.
- R and R can. be trans.
- R 3 can be OR a and R 9 can be (CH 2 ) n OR b .
- R 3 and R 9 can be cis, or R 3 and R 9 can be trans.
- n can be 1 or 2.
- R 3 canbeOR b andR 9 canbe(CH 2 ) n OR a ;orR 3 canbeOR b andR 9 canbe(CH 2 ) n OR a .
- R 14 can be N(CH3)R 7 .
- R 7 can be (CH 2 ) 5 NHR d or (CH 2 ) 5 NHR d .
- R d can be chosen from the group of a folic acid radical; a cholesterol radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical.
- R d is a cholesterol radical.
- this invention features an oligonucleotide agent comprising at least one subunit having a structure of formula (II):
- X is N(CO)R 7 or NR 7 ;
- Each of R 1 and R 2 is, independently, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that one of R 1 and R 2 is OR a or OR b and the other is (CH 2 ) n OR a or (CH 2 ) n OR b (when the SRMS is terminal, one of R 1 or R 2 will include R a and one will include R b ; when the SRMSS is internal, both R 1 and R 2 will each include an R b );further provided that preferably OR a may only be present with (CH 2 ) n OR b and (CH 2 ) n OR a may only be present with OR b ; R 7 is C 1 -C 20 alkyl substituted withNR c R d ; R 8 is C 1 -C 6 alkyl;
- R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;
- R 14 is NR c R 7 ;
- R a is:
- R b is
- Each of A and C is, independently, O or S; B is OH, O ' , or
- R c is H or C 1 -C 6 alkyl
- R d is H or a ligand; and n is 1-4.
- the oligonucleotide agent of the conjugate is substantially single-stranded and comprises from about 12 to about 29 subunits, preferably about 15 to about 25 subunits.
- An oligonucleotide agent that is substantially single-stranded includes at least 60%, 70% , 80%, or 90% or more nucleotides that are not duplexed.
- Embodiments can include one or more of the features described above.
- this invention features an oligonucleotide agent having at least one subunit comprising formula (I) or formula (II).
- this invention features an oligonucleotide agent having at least two subunits comprising formula (I) and/or formula (II).
- this invention provides a method of making an oligonucleotide agent described herein having at least one subunit comprising formula (I) and/or (II).
- this invention provides a method of modulating expression of a target gene. The method includes administering an oligonucleotide agent described herein having at least one subunit comprising formula (I) and/or (II) to a subject.
- this invention features a pharmaceutical composition having an oligonucleotide agent described herein having at least one subunit comprising formula (I) and/or (II) and a pharmaceutically acceptable carrier.
- SRMSs or tethers described herein may be incorporated into any oligonucleotide agent described herein.
- An oligonucleotide agent may include one or more of the SRMSs described herein.
- An SRMS can be introduced at one or more points in an oligonucleotide agent.
- An SRMS can be placed at or near (within 1, 2, or 3 positions) the 3' or 5' end of the oligonucleotide. In some embodiments, it is preferred to not have an SRMS at or near (within 1, 2, or 3 positions of) the 5' end of the oligonucleotide.
- An SRMS can be internal, and will preferably be positioned in regions not critical for binding to the target.
- an oligonucleotide agent may have an SRMS at (or within 1, 2, or 3 positions of) the 3' end.
- an oligonucleotide agent may have an SRMS at an internal position. In other embodiments, an oligonucleotide agent may have an SRMS at the 3' end and an SRMS at an internal position.
- the oligonucleotide agents can take an architecture or structure described herein.
- the oligonucleotide agent can be selected to target any of abroad spectrum of genes, including any of the genes described herein.
- the oligonucleotide agent has an architecture (architecture refers to one or more of the overall length) described herein.
- architecture refers to one or more of the overall length
- the invention features an oligonucleotide agent to which is conjugated a lipophilic moiety, e.g., cholesterol, e.g., by conjugation to an SRMS of an oligonucleotide agent.
- the lipophilic moiety enhances entry of the oligonucleotide agent into a cell.
- the cell is part of an organism, tissue, or cell line, e.g., a primary cell line, immortalized cell line, or any type of cell line disclosed herein.
- the conjugated oligonucleotide agent can be used to inhibit expression of a target gene in an organism, tissue, or cell line, e.g., a primary cell line, immortalized cell line, or any type of cell line disclosed herein.
- Il organism e.g., a mammal, e.g., a human, or to inhibit expression of a target gene in a cell line or in cells which are outside an organism.
- the lipophilic moiety can be chosen, for example, from the group consisting of a lipid, cholesterol, oleyl, retinyl, cholesteryl residues, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.
- a preferred lipophilic moiety is cholesterol.
- the oligonucleotide agent can have at least one subunit having formula (I) or formula (II) incorporated into it.
- the oligonucleotide agent can have one or more of any of the features described herein.
- R d can be cholesterol
- X can be N(CO)R 7 or NR 7
- Y can be CR 9 R 10
- Z can be absent
- R 1 can be (CH 2 ) n OR b and R 3 can be OR a
- X can be N(CO)R 7 or NR 7
- Y can be CR 9 R 10
- Z can be CR 11 R 12
- R 9 can be (CH 2 ) n OR b and R 10 can be OR a
- X can be N(CO)R 7 or NR 7
- Y can be NR 8
- Z can be CR 11 R 12
- R 1 can be (CH 2 ) n OR b and R 3 can be OR
- the lipophilic moiety e.g., a cholesterol
- a myocyte can be a smooth muscle cell or a cardiac myocyte
- a fibroblast cell can be a dermal fibroblast
- a leukocyte can be a monocyte.
- the cell can be from an adherent tumor cell line derived from a tissue, such as bladder, lung, breast, cervix, colon, pancreas, prostate, kidney, liver, skin, or nervous system ⁇ e.g., central nervous system).
- a tissue such as bladder, lung, breast, cervix, colon, pancreas, prostate, kidney, liver, skin, or nervous system ⁇ e.g., central nervous system).
- the invention provides, methods of inhibiting expression of a target gene by providing an oligonucleotide agent to which a lipophilic moiety is conjugated, e.g., a lipophilic conjugated oligonucleotide agent described herein, to a cell.
- an oligonucleotide agent to which a lipophilic moiety is conjugated, e.g., a lipophilic conjugated oligonucleotide agent described herein, to a cell.
- the conjugated oligonucleotide agent can be used to inhibit expression of a target gene in an organism, e.g., a mammal, e.g., a human, or to inhibit expression of a target gene in a cell line or in cells which are outside an organism, hi the case of a whole organism, the method can be used to inhibit expression of a gene, e.g., a gene described herein, and treat a condition mediated by the gene.
- the oligonucleotide agent to which a lipophilic moiety is conjugated can be used to inhibit expression of a gene, e.g., one described herein.
- Cells which are not part of a whole organism can be used in an initial screen to determine if an oligonucleotide agent is effective in inhibiting expression of a gene.
- a test in cells which are not part of a whole organism can be followed by testing the oligonucleotide agent in a whole animal, m preferred embodiments, the oligonucleotide agent which is conjugated to a lipophilic moiety is administered to an organism, or contacted with a cell which is not part of an organism, in the absence of (or in a reduced amount of) other reagents that facilitate or enhance delivery, e.g., a compound which enhances transit through the cell membrane.
- a reduced amount can be an amount of such reagent which is reduced in comparison to what would be needed to get an equal amount of nonconjugated oligonucleotide agent into the target cell).
- the oligonucleotide agent which is conjugated to a lipophilic moiety is administered to an organism, or contacted with a cell which is not part of an organism, in the absence (or reduced amount) of: an additional lipophilic moiety; a transfection agent, e.g., concentrations of an ion or other substance which substantially alters cell permeability to an oligonucleotide agent; a transfecting agent such as LipofectamineTM (Invitrogen, Carlsbad, CA), Lipofectamine 2000TM, TransIT-TKOTM (Mirus, Madison, WT), FuGENE 6 (Roche, Indianapolis, IN), polyethylenimine, X-tremeGENE Q2 (Roche, Indianapolis, IN), DOTAP, DOSPER, MetafecteneTM (Biontex, Kunststoff, Germany), and the like.
- a transfection agent e.g., concentrations of an ion or other substance which substantially alters cell permeability to an oligonucleotide
- the oligonucleotide agent is suitable for delivery to a cell in vivo, e.g., to a cell in an organism.
- the oligonucleotide agent is suitable for delivery to a cell in vitro, e.g., to a cell in a cell line.
- an oligonucleotide agent to which a lipophilic moiety is attached can target any gene described herein and can be delivered to any cell type described herein, e.g., a cell type in an organism, tissue, or cell line. Delivery of the oligonucleotide agent can be in vivo, e.g., to a cell in an organism, or in vitro, e.g., to a cell in a cell line.
- the invention provides compositions of oligonucleotide agents described herein, and in particular compositions of an oligonucleotide agent to which a lipophilic moiety is conjugated, e.g., a lipophilic conjugated oligonucleotide agent described herein.
- the composition is a pharmaceutically acceptable composition.
- the composition e.g., pharmaceutically acceptable composition
- a reduced amount can be an amount of such reagent which is reduced in comparison to what would be needed to get an equal amount of nonconjugated oligonucleotide agent into the target cell).
- the composition is free of, has a reduced amount of, or is essentially free of: an additional lipophilic moiety; a transfection agent, e.g., concentrations of an ion or other substance which substantially alters cell permeability to an oligonucleotide agent; a transfecting agent such as LipofectamineTM (Invitrogen, Carlsbad, CA), Lipofectamine 2000TM, TransIT- TKOTM (Minis, Madison, WI), FuGENE 6 (Roche, Indianapolis, IN), polyethylenimine, X- tremeGENE Q2 (Roche, Indianapolis, IN), DOTAP, DOSPER, MetafecteneTM (Biontex, Kunststoff, Germany), and the like.
- a transfection agent e.g., concentrations of an ion or other substance which substantially alters cell permeability to an oligonucleotide agent
- a transfecting agent such as LipofectamineTM (Invitrogen, Carlsbad, CA), Lipofectamine 2000TM
- composition is suitable for delivery to a cell in vivo, e.g., to a cell in an organism.
- the oligonucleotide agent is suitable for delivery to a cell in vitro, e.g., to a cell in a cell line.
- the SRMS-containing oligonucleotide agents can be used in any of the methods described herein, e.g., to target any of the genes described herein or to treat any of the disorders described herein. They can be incorporated into any of the formulations, modes of delivery, delivery modalities, kits or preparations, e.g., pharmaceutical preparations, described herein. E.g, a kit which includes one or more of the oligonucleotide agents described herein, a sterile container in which the oligonucleotide agent is disclosed, and instructions for use.
- compositions of the invention e.g., the SRMS-containing oligonucleotide agents described herein, can be used with any of the oligonucleotide agents described herein.
- methods and compositions of the invention can be used for the treatment of any disease or disorder described herein, and for the treatment of any subject, e.g., any animal, any mammal, such as any human.
- compositions of the invention e.g., the SRMS-containing oligonucleotide agents described herein, can be used with any dosage and/or formulation described herein, as well as with any route of administration described herein.
- the non-ribose scaffolds, as well as monomers and dimers of the SRMSs described herein are within the invention.
- oligonucleotide agent refers to a single stranded oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or both or modifications thereof, which is antisense with respect to its target.
- This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly.
- Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.
- Oligonucleotide agents include both nucleic acid targeting (NAT) oligonucleotide agents and protein-targeting (PT) oligonucleotide agents.
- NAT and PT oligonucleotide agents refer to single stranded oligomers or polymers of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or both or modifications thereof.
- RNA ribonucleic acid
- DNA deoxyribonucleic acid
- This term includes oligonucleotides composed of naturally occurring nucleobases, sugars, and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions that function similarly.
- NATs designed to bind to specific RNA or DNA targets have substantial complementarity, e.g., at least 70, 80, 90, or 100% complementary, with at least 10, 20, or 30 or more bases of a target nucleic acid, and include antisense RNAs, miRNAs, and other non-duplex structures which can modulate expression.
- Other NAT oligonucleotide agents include external guide sequence (EGS) oligonucleotides (oligozymes), DNAzymes, and ribozymes.
- the NAT oligonucleotide agents can target any nucleic acid, e.g., a miRNA, a pre-miRNA, a pre-mRNA, an mRNA, or a DNA. These NAT oligonucleotide agents may or may not bind via Watson-Crick complementarity to their targets.
- PT oligonucleotide agents bind to protein targets, preferably by virtue of three-dimensional interactions, and modulate protein activity. They include decoy RNAs, aptamers, and the like.
- the compounds in accordance with this invention preferably comprise from about 5 to about 100 nucleobases, e.g., from about 8 to about 75 nucleobases, e.g., from about 8 to about 50 nucleobases.
- NAT oligonucleotide agents are preferably about 12 or about 15 nucleotides long, more preferably about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long.
- PT oligonucleotide agents are preferably about 18 nucleotides long, more preferably 23.
- Particularly preferred compounds are miRNAs and antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases.
- an oligonucleotide agent may act by one or more of a number of mechanisms, including a cleavage-dependent or cleavage-independent mechanism.
- a cleavage-based mechanism can be RNAse H dependent and/or can include RISC complex function.
- Cleavage-independent mechanisms include occupancy-based translational arrest, such as can be mediated by miRNAs, or binding of the oligonucleotide agent to a protein, as do aptamers.
- Oligonucleotide agents may also be used to alter the expression of genes by changing the choice of splice site in a pre-mRNA. Inhibition of splicing can also result in degradation of the improperly processed message, thus down-regulating gene expression.
- An oligonucleotide agent can be administered, e.g., to a cell or to a human, in a single- stranded or double-stranded configuration.
- An oligonucleotide agent that is in a double-stranded configuration is bound to a substantially complementary oligonucleotide strand. Delivery of an oligonucleotide agent in a double stranded configuration may confer certain advantages on the oligonucleotide agent, such as an increased resistance to nucleases.
- one or both of the oligonucleotide agent and the substantially complementary strand can include modifications, e.g., any of the modifications described herein, including base modifications, sugar modifications, tethered ligands, and the like.
- an oligonucleotide agent featured in the invention can target a substantially complementary miRNA.
- an oligonucleotide agent can target an endogenous miRNA, such as an miRNA associated with a particular disease or disorder.
- an oligonucleotide agent targets an miRNA that is upregulated in tumor cells, e.g., lung tumor cells.
- the oligonucleotide agent can target miR-21 (Shingara et al, Ambion TechNotes 11(6), 2005).
- an oligonucleotide agent targets an miRNA that has been found to be upregulated in diffuse large B cell lymphoma (DLBCL) or in Burkitt's Lymphoma.
- DLBCL diffuse large B cell lymphoma
- Burkitt's Lymphoma Burkitt's Lymphoma.
- the oligonucleotide agent can target miR-155 (Eis et al., Proc. Natl. Acad. ScL U.S.A. 102:3627-3632, 2005; Metzler et al., Genes Chromosom. Cancer 39:167-169, 2004).
- an oligonucleotide agent targets an miRNA that is enriched in particular tissues or in particular cell types, e.g., in pancreatic islet cells.
- the oligonucleotide agent can target miR-375, a pancreatic islet-specific miRNA that has been shown to suppress glucose-induced insulin secretion (Poy et al, Nature 432:226-230, 2004).
- an miRNA oligonucleotide agent featured in the invention targets an endogenous miRNA that binds a gene for which underexpression is associated with disease. Targeting of such an miRNA with an miRNA oligonucleotide agent will result in upregulation of the disease-associated gene, thereby relieving symptoms of the disease or disorder.
- Exemplary single stranded oligonucleotide agents can target RNAs encoding the following polypeptides: vascular endothelial growth factor (VEGF); Apoliprotein B (ApoB); luciferase (luc); Androgen Receptor (AR); coagulation factor VII (FVII); hypoxia-inducible factor 1, alpha subunit (Hif-l ⁇ ); placenta growth factor (PLGF); Lamin A/C; and green fluorescent protein (GFP).
- VEGF vascular endothelial growth factor
- ApoB Apoliprotein B
- luc luciferase
- AR Androgen Receptor
- FVII coagulation factor VII
- Hif-l ⁇ hypoxia-inducible factor 1 alpha subunit
- PLGF placenta growth factor
- Lamin A/C Lamin A/C
- green fluorescent protein GFP
- miRNA targets are described, e.g., in John et al, PLoS Biology 2:1862-1879, 2004 (correction in PLoS 3:1328, 2005), and The microRNA Registry (Griffiths- Jones S., NAR 32:D1O9-D111, 2004).
- An oligonucleotide agent featured in the invention can include a nucleotide sequence that is substantially identical to a nucleotide sequence of an miRNA, such as an endogenous miRNA.
- An oligonucleotide sequence that is substantially identical to a second nucleotide sequence is 70%, 80%, 90%, or more identical to the second nucleotide sequence.
- the agent is identical in sequence with an endogenous miRNA.
- an oligonucleotide agent that is substantially identical to a nucleotide sequence of an miRNA can be delivered to a cell or a human to replace or supplement the activity of an endogenous miRNA, such as when an miRNA deficiency is linked to a disease or disorder, hi one embodiment, an oligonucleotide agent featured in the invention can have a nucleotide sequence that is substantially identical to an miRNA known to be down-regulated or lost in certain cancers.
- an oligonucleotide agent can have a nucleotide sequence that is substantially identical to miR-15 (e.g., miR-15a or miR-15b) or miR- 16, miRNAs known to be downregulated or lost in many cases of B cell chronic lymphocytic leukemia, mantle cell lymphoma, multiple myelomas and prostate cancer (Callin et ah, Proc. Natl. Acad. ScL 99:15524-15529, 2002).
- miR-15 e.g., miR-15a or miR-15b
- miR- 16 miRNAs known to be downregulated or lost in many cases of B cell chronic lymphocytic leukemia, mantle cell lymphoma, multiple myelomas and prostate cancer
- an oligonucleotide agent can have a nucleotide sequence that is substantially identical to miR-143 or miR-145, miRNAs known to be downregulated in many cases of adenomatous and cancer stages of colorectal neoplasia (Micheal et ah, MoI. Cancer Res. 1:882-891, 2003).
- an oligonucleotide agent can have a nucleotide sequence that is substantially identical to let-7, an miRNA known to be downregulated in lung cancer tissue (Johnson et ah, Cell 120:635-647, 2005).
- Oligonucleotide agents that are substantially identical to at least a portion of an miRNA, such as those described above, can be administered to a subject to treat the disease or disorder associated with the downregulation of miRNA expression.
- Other suitable oligonucleotide agents are substantially identical to miRNAs described, e.g., in John et ah, PLoS Biology 2:1862-1879, 2004 (correction in PLoS 3:1328, 2005), and The microRNA Registry (Griffiths- Jones, NAR 32:D1O9-D111, 2004).
- Oligonucleotide agents include microRNAs (miRNAs).
- MicroRNAs are small noncoding RNA molecules that are capable of causing post-transcriptional silencing of specific genes in cells such as by the inhibition of translation or through degradation of the targeted mRNA.
- An miRNA can be completely complementary or can have a region of noncomplementarity with a target nucleic acid, consequently resulting in a "bulge" at the region of non-complementarity.
- the region of noncomplementarity (the bulge) can be flanked by regions of sufficient complementarity, preferably complete complementarity to allow duplex formation.
- the regions of complementarity are at least 8 to 10 nucleotides long (e.g, 8, 9, or 10 nucleotides long).
- a miRNA can inhibit gene expression by repressing translation, such as when the microRNA is not completely complementary to the target nucleic acid, or by causing target RNA degradation, which is believed to occur only when the miRNA binds its target with perfect complementarity.
- the invention also can include double-stranded precursors of miRNAs that may or may not form a bulge when bound to their targets.
- an oligonucleotide agent featured in the invention can target an endogenous miRNA or pre-miRNA.
- the oligonucleotide agent featured in the invention can include naturally occurring nucleobases, sugars, and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions that function similarly.
- Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for the endogenous miRNA target, and/or increased stability in the presence of nucleases.
- An oligonucleotide agent designed to bind to a specific endogenous miRNA has substantial complementarity, e.g., at least 70, 80, 90, or 100% complementary, with at least 10, 20, or 25 or more bases of the target miRNA.
- a miRNA or pre-miRNA can be 18-100 nucleotides in length, and more preferably from 18-80 nucleotides in length.
- Mature miRNAs can have a length of 19-30 nucleotides, preferably 21-25 nucleotides, particularly 21, 22, 23, 24, or 25 nucleotides.
- MicroRNA precursors can have a length of 70-100 nucleotides and have a hairpin conformation.
- MicroRNAs can be generated in vivo from pre-miRNAs by enzymes called Dicer and Drosha that specifically process long pre- miRNA into functional miRNA.
- the microRNAs or precursor mi-RNAs featured in the invention can be synthesized in vivo by a cell-based system or can be chemically synthesized.
- MicroRNAs can be synthesized to include a modification that imparts a desired characteristic.
- the modification can improve stability, hybridization thermodynamics with a target nucleic acid, targeting to a particular tissue or cell-type, or cell permeability, e.g., by an endocytosis-dependent or -independent mechanism. Modifications can also increase sequence specificity, and consequently decrease off-site targeting. Methods of synthesis and chemical modifications are described in greater detail below.
- an miRNA Given a sense strand sequence (e.g., the sequence of a sense strand of a cDNA molecule), an miRNA can be designed according to the rules of Watson and Crick base pairing.
- the miRNA can be complementary to a portion of an RNA, e.g., a miRNA, a pre-miRNA, a pre- mRNA or an mRNA.
- the miRNA can be complementary to the coding region or noncoding region of an mRNA or pre-mRNA, e.g., the region surrounding the translation start site of a pre-mRNA or mRNA, such as the 5' UTR.
- An miRNA oligonucleotide can be, for example, from about 12 to 30 nucleotides in length, preferably about 15 to 28 nucleotides in length (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length).
- an miRNA or a pre-miRNA featured in the invention can have a chemical modification on a nucleotide in an internal (i.e., non-terminal) region having noncomplementarity with the target nucleic acid.
- a modified nucleotide can be incorporated into the region of a miRNA that forms a bulge.
- the modification can include a ligand attached to the miRNA, e.g., by a linker (e.g., see diagrams OT-I through OT-IV below).
- the modification can, for example, improve pharmacokinetics or stability of a therapeutic miRNA, or improve hybridization properties (e.g., hybridization thermodynamics) of the miRNA to a target nucleic acid.
- the orientation of a modification or ligand incorporated into or tethered to the bulge region of a miRNA is oriented to occupy the space in the bulge region.
- the modification can include a modified base or sugar on the nucleic acid strand or a ligand that functions as an intercalator. These are preferably located in the bulge.
- the intercalator can be an aromatic, e.g., a polycyclic aromatic or heterocyclic aromatic compound.
- a polycyclic intercalator can have stacking capabilities, and can include systems with 2, 3, or 4 fused rings.
- the universal bases described below can be incorporated into the miRNAs.
- an miRN A or a pre-miRNA can include an aminoglycoside ligand, which can cause the miRNA to have improved hybridization properties or improved sequence specificity.
- Exemplary aminoglycosides include glycosylated polylysine; galactosylated polylysine; neomycin B; tobramycin; kanamycin A; and acridine conjugates of aminoglycosides, such as Neo-N-acridine, Neo-S-acridine, Neo-C-acridine, Tobra-N-acridine, and KanaA-N- acridine.
- Use of an acridine analog can increase sequence specificity.
- neomycin B has a high affinity for RNA as compared to DNA, but low sequence-specificity.
- an acridine analog, neo-S-acridine has an increased affinity for the HTV Rev-response element (RRE).
- the guanidine analog (the guanidinoglycoside) of an aminoglycoside ligand is tethered to an oligonucleotide agent.
- the amine group on the amino acid is exchanged for a guanidine group. Attachment of a guanidine analog can enhance cell permeability of an oligonucleotide agent.
- the ligand can include a cleaving group that contributes to target gene inhibition by cleavage of the target nucleic acid.
- the cleaving group is tethered to the miRNA in a manner such that it is positioned in the bulge region, where it can access and cleave the target RNA.
- the cleaving group can be, for example, a bleomycin (e.g., bleomycin- A 5 , bleomycin- A 2; or bleomycin-B 2 ), pyrene, phenanthrolme ⁇ e.g., O-phenanthroline), a polyamine, a tripeptide (e.g., lys-tyr-lys tripeptide), or metal ion chelating group.
- a bleomycin e.g., bleomycin- A 5 , bleomycin- A 2; or bleomycin-B 2
- pyrene e.g., bleomycin- A 5 , bleomycin- A 2; or bleomycin-B 2
- pyrene e.g., bleomycin- A 5 , bleomycin- A 2; or bleomycin-B 2
- pyrene e.g., bleomycin- A 5 , bleomycin
- the metal ion chelating group can include, e.g., an Lu(III) or EU(IH) macrocyclic complex, a Zn(IT) 2,9- dimethylphenanthroline derivative, a Cu(II) terpyridine, or acridine, which can promote the selective cleavage of target RNA at the site of the bulge by free metal ions, such as Lu(IIT).
- a peptide ligand can be tethered to a miRNA or a pre-miRNA to promote cleavage of the target RNA, e.g., at the bulge region.
- l,8-dimethyl-l,3,6,8,10,13- hexaazacyclotetradecane can be conjugated to a peptide (e.g., by an amino acid derivative) to promote target RNA cleavage.
- a peptide e.g., by an amino acid derivative
- the methods and compositions featured in the invention include miRNAs that inhibit target gene expression by a cleavage or non-cleavage dependent mechanism.
- An miRNA or a pre-miRNA can be designed and synthesized to include a region of noncomplementarity (e.g., a region that is 3, 4, 5, or 6 nucleotides long) flanked by regions of sufficient complementarity to form a duplex (e.g., regions that are 7, 8, 9, 10, or 11 nucleotides long).
- a region of noncomplementarity e.g., a region that is 3, 4, 5, or 6 nucleotides long
- regions of sufficient complementarity to form a duplex e.g., regions that are 7, 8, 9, 10, or 11 nucleotides long.
- the miRNA sequences can include 2'-O-methyl, 2'-fluorine, 2'-O-methoxyethyl, 2'-O-aminopropyl, T- amino, and/or phosphorothioate linkages.
- Inclusion of locked nucleic acids (LNA), 2- thiopyrimidines (e.g., 2-thio-U), 2-amino-A, G-clamp modifications, and ethylene nucleic acids (ENA), e.g., 2'-4'-ethylene-bridged nucleic acids, can also increase binding affinity to the target.
- furanose sugars in the oligonucleotide backbone can also decrease endonucleolytic cleavage.
- An miRNA or a pre-miRNA can be further modified by including a 3' cationic group, or by inverting the nucleoside at the 3'-terminus with a 3'-3' linkage.
- the 3'-terminus can be blocked with an aminoalkyl group, e.g., a 3' C5- aminoalkyl dT.
- Other 3' conjugates can inhibit 3 '-5' exonucleolytic cleavage.
- a 3' conjugate such as naproxen or ibuprofen
- Even small alkyl chains, aryl groups, or heterocyclic conjugates or modified sugars can block 3'-5'-exonucleases.
- the 5' -terminus can be blocked with an aminoalkyl group, e.g., a 5'-O-alkylamino substituent.
- Other 5* conjugates can inhibit 5'-3' exonucleolytic cleavage.
- a 5' conjugate such as naproxen or ibuprofen, may inhibit exonucleolytic cleavage by sterically blocking the exonuclease from binding to the 5' end of oligonucleotide.
- Even small alkyl chains, aryl groups, or heterocyclic conjugates or modified sugars can block 3'-5'-exonucleases.
- an miRNA or a pre-miRNA includes a modification that improves targeting, e.g. a targeting modification described herein.
- modifications that target miRNA molecules to particular cell types include carbohydrate sugars such as galactose, N- acetylgalactosamine, ma ⁇ nose; vitamins such as folates; other ligands such as RGDs and RGD mimics; and small molecules including naproxen, ibuprofen or other known protein-binding molecules.
- An miRNA or a pre-miRNA can be constructed using chemical synthesis and/or enzymatic ligation reactions using procedures known in the art.
- an miRNA or a pre-miRNA can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the miRNA or a pre-miRNA and target nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
- target nucleic acids e.g., phosphorothioate derivatives and acridine substituted nucleotides.
- Other appropriate nucleic acid modifications are described herein.
- the miRNA or pre-miRNA nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).
- the single-stranded oligonucleotide agents featured in the invention include antisense nucleic acids.
- An "antisense" nucleic acid includes a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a gene expression product, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an RNA sequence, e.g. , a pre- mRNA, mRNA, miRNA, or pre-miRNA. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid target.
- antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing.
- the antisense nucleic acid molecule can be complementary to a portion of the coding or noncoding region of an RNA, e.g. , a pre-mRNA or mRNA.
- the antisense oligonucleotide can be complementary to the region surrounding the translation start site of a pre-mRNA or mRNA, e.g., the 5' UTR.
- An antisense oligonucleotide can be, for example, about 10 to 25 nucleotides in length (e.g., 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, or 24 nucleotides in length).
- An antisense oligonucleotide can also be complementary to a miRNA or pre-miRNA.
- An antisense nucleic acid can be constructed using chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid
- an antisense oligonucleotide can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and target nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Other appropriate nucleic acid modifications are described herein.
- the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).
- An antisense agent can include ribonucleotides only, deoxyribonucleotides only (e.g., oligodeoxynucleotides), or both deoxyribonucleotides and ribonucleotides.
- an antisense agent consisting only of ribonucleotides can hybridize to a complementary RNA, and prevent access of the translation machinery to the target RNA transcript, thereby preventing protein synthesis.
- An antisense molecule including only deoxyribonucleotides, or deoxyribonucleotides and ribonucleotides, e.g., DNA sequence flanked by RNA sequence at the 5' and 3' ends of the antisense agent, can hybridize to a complementary RNA, and the RNA target can be subsequently cleaved by an enzyme, e.g., RNAse H. Degradation of the target RNA prevents translation.
- the flanking RNA sequences can include 2'-O-methylated nucleotides, and phosphorothioate linkages, and the internal DNA sequence can include phosphorothioate internucleotide linkages.
- the internal DNA sequence is preferably at least five nucleotides in length when targeting by RNAseH activity is desired.
- an antisense agent can be further modified by inverting the nucleoside at the 3'-terminus with a 3'-3' linkage.
- the 3'-terminus can be blocked with an aminoalkyl group.
- an antisense oligonucleotide agent includes a modification that improves targeting, e.g. a targeting modification described herein.
- An oligonucleotide agent featured in the invention can be a decoy nucleic acid, e.g., a decoy RNA.
- a decoy nucleic acid resembles a natural nucleic acid, but is modified in such a way as to inhibit or interrupt the activity of the natural nucleic acid.
- a decoy RNA can mimic the natural binding domain for a ligand.
- the decoy RNA therefore competes with natural binding target for the binding of a specific ligand.
- the natural binding target can be an endogenous nucleic acid, e.g., a pre-miRNA, miRNA, premRNA, mRNA or DNA.
- TAR RNA HIV trans-activation response
- a decoy RNA includes a modification that improves targeting, e.g. a targeting modification described herein.
- An oligonucleotide agent featured in the invention can be an aptamer.
- An aptamer binds to a non-nucleic acid ligand, such as a small organic molecule or protein, e.g., a transcription or translation factor, and subsequently modifies (e.g. , inhibits) activity.
- An aptamer can fold into a specific structure that directs the recognition of the targeted binding site on the non-nucleic acid ligand.
- An aptamer can contain any of the modifications described herein.
- an aptamer includes a modification that improves targeting, e.g. a targeting modification described herein.
- the chemical modifications described above for miRNAs and antisense RNAs, and described elsewhere herein, are also appropriate for use in decoy nucleic acids.
- FIG. 1 a general synthetic scheme for incorporation of SRMS monomers into an oligonucleotide.
- FIG. 2A is a list of substituents that may be present on silicon in OFG 1 .
- FIG. 2B is a list of substituents that may be present on the C2'-orthoester group.
- FIG. 3 is list of representative cyclic, sugar replacement monomer subunit (SRMS) carriers.
- Panel 1 shows pyrroline-based SRMSs;
- panel 2 shows 3-hydroxyproline-based SRMSs;
- panel 3 shows piperidine-based SRMSs;
- panel 4 shows morpholine and piperazine- based SRMSs;
- panel 5 shows decalin-based SRMSs.
- Rl is succinate or phosphoramidate and R2 is H or a conjugate ligand.
- FIG. 4 is a general reaction scheme for 3' conjugation of peptide into an oligonucleotide agent.
- FIG. 5 is a general reaction scheme for 5' conjugation of peptide into an oligonucleotide agent.
- FIG. 6 is a general reaction scheme for the synthesis of aza-peptides.
- FIG. 7 is a general reaction scheme for the synthesis of N-methyl amino acids and peptides.
- FIG. 8 is a general reaction scheme for the synthesis of ⁇ -methyl amino acids and Ant and Tat peptides.
- FIG. 9 is a general reaction scheme for the synthesis of Ant and Tat oligocarbamates.
- FIG. 10 is a a general reaction scheme for the synthesis of Ant and Tat oligoureas.
- FIG. 11 is a schematic representation of peptide carriers.
- FIG. 12. is a list of representative cholesterol-tethered SRMS monomers.
- FIG. 13 shows LCMS data for a 3' cholesterol conjugate after PAGE purification.
- FIG. 14 is a denaturing gel analysis of the human serum stability assay for AL-DUP- 1000.
- C is the 4 hour time point for siRNA duplex incubated in PBS buffer alone
- OH- is the partial alkaline hydrolysis marker
- *s/as represents siRNA duplex containing 5' end-labeled sense RNA
- s/*as represents duplex containing 5' end-labeled antisense RNA.
- Samples were incubated in 90% human serum and time points were assayed at 10 seconds, 5 min, 15 min, 30 min, 1 hour, 2 hours and 4 hours. Black lines to the right of bands indicate exonucleolytic degradation fragments and the red lines highlight a few of the endonucleolytic degradation fragment.
- FIG. 14 is a denaturing gel analysis of the human serum stability assay for AL-DUP- 1000.
- C is the 4 hour time point for siRNA duplex incubated in PBS buffer alone
- OH- is the partial alkaline hydrolysis marker
- 15A is a denaturing gel analysis of the human serum stability assay for AL-DUP- 1393.
- C is the 4 hour time point for each siRNA duplex incubated in PBS buffer alone, *s/as represents siRNA duplex containing 5' end-labeled sense RNA and s/*as represents duplex containing 5' end-labeled antisense RNA. Samples were assayed at 10 seconds, 15 min, 30 min, 1 hour, 2 hours and 4 hours.
- FIG. 15B is a denaturing gel analysis of the human serum stability assay for AL-DUP- 1329. The lanes are labeled and the experiment was performed as described for FIG. 15 A.
- FIG. 16 is a denaturing gel analysis of AL-DUP- 1036, AL-DUP-13ff, and AL-DUP-1363 (see Table 12 for sequences). Black vertical lines highlight regions where exonuclease cleavage is suppressed, stars indicate sites of strong endonucleolytic cleavage in the antisense strand and weaker endonucleolytic cleavage in the sense strand.
- C is the 4 hour time point for each siRNA duplex incubated in PBS buffer alone, *s/as represents siRNA duplex containing 5' end-labeled sense RNA and s/*as represents duplex containing 5' end-labeled antisense RNA.
- FIG. 17 Human serum stability profile of siRNA duplexes containing cationic modifications.
- Denaturing gel analysis of AL-DUP-10aa (alkylamino-dT), AL-DUP-lccc (abasic pyrrolidine cationic), and AL-DUP-1403 see Table 13 for sequences). Black line highlights region where exonuclease cleavage is suppressed and red star indicates site of strong endonucleolytic cleavage in the antisense strand.
- C is the 4 hour time point for each siRNA duplex incubated in PBS buffer alone, *s/as represents siRNA duplex containing 5' end-labeled sense RNA and s/*as represents duplex containing 5' end-labeled antisense RNA. Samples were assayed at 10 seconds, 15 min, 30 min, 1 hour, 2 hours and 4 hours.
- FIG. 18 is a denaturing gel analysis of the human serum stability assay for AL-DUP- 1069.
- the black vertical line highlights the region where exonuclease cleavage is suppressed.
- C is the 4 hour time point for each siRNA duplex incubated in PBS buffer alone, *s/as represents siRNA duplex containing 5' end-labeled sense RNA and s/*as represents duplex containing 5' end-labeled antisense RNA. Samples were assayed at 10 seconds, 15 min, 30 min, 1 hour, 2 hours and 4 hours.
- FIG. 19A is a panel of Northern blots of total RNA (15 ⁇ g) isolated from mouse liver 24 h after injection of differently modified RNAs (240 mg/kg) targeting miR-122. Samples were separated in 14%-polyacrylamide gels in the absence of formamide, and the membranes were probed for miR-122. Ethidium bromide staining of tRNA is shown as a loading control.
- FIG. 19B is a panel of Northern blots of total RNA (15 ⁇ g) isolated from mouse liver 24 h after injection of differently modified RNAs (240 mg/kg) against miR-122.
- FIG. 19C is a panel of Northern blots of total RNA (15 ⁇ g) isolated from mouse liver 24 h after injection of differently modified RNAs (240 mg/kg) against miR-122. Samples were separated in 14%-polyacrylamide gels in the presence of 20% formamide, and the membranes were probed for miR-122. Ethidium bromide staining of tRNA is shown as a loading control.
- FIG. 2OB is a panel of Northern blots of total RNA (15 ⁇ g) isolated from mouse livers. RNA was isolated 3, 6, 9, 13, and 23 days after injection of antagomir-122. Membranes were probed for both the endogenous miR-122 and the injected antagomir-122. Ethidium bromide staining of tRNA is shown as a loading control.
- the subject is a mammal such as a cow, horse, mouse, rat, dog, pig, goat, or a primate.
- the subject can be a dairy mammal (e.g., a cow, or goat) or other farmed animal (e.g., a chicken, turkey, sheep, pig, fish, shrimp), m a much preferred embodiment, the subject is a human, e.g., a normal individual or an individual that has, is diagnosed with, or is predicted to have a disease or disorder.
- oligonucleotide agent-mediated modulation persists for several days after administering the oligonucleotide agent composition, in many instances it is possible to administer the composition with a frequency of less than once per day, or, for some instances, only once for the entire therapeutic regimen.
- treatment of some cancer cells may be mediated by a single bolus administration, whereas a chronic viral infection may require regular administration, e.g., once per week or once per month.
- treatment of diffuse large B cell lymphoma (DLBCL) or Burkitt's lymphoma may be treated with a single bolus administration of a single-stranded oligonucleotide agent, e.g., a single-stranded oligonucleotide agent that targets miR-155.
- a single-stranded oligonucleotide agent e.g., a single-stranded oligonucleotide agent that targets miR-155.
- oligonucleotide agent can be formulated according to an exemplary method described herein.
- halo refers to any radical of fluorine, chlorine, bromine or iodine.
- alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C 1 -C 12 alkyl indicates that the group may have from 1 to 12 (inclusive) carbon atoms in it.
- haloalkyl refers to an alkyl in which one or more hydrogen atoms are replaced by halo, and includes alkyl moieties in which all hydrogens have been replaced by halo (e.g., perfluoroalkyl). Alkyl and haloalkyl groups may be optionally inserted with O, N, or S.
- aralkyl refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of
- alkenyl refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms and characterized in having one or more double bonds. Examples of a typical alkenyl include, but not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl groups.
- alkynyl refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms and characterized in having one or more triple bonds. Some examples of a typical alkynyl are ethynyl, 2-propynyl, and 3-methylbutynyl, and propargyl. The sp 2 and sp 3 carbons may optionally serve as the point of attachment of the alkenyl and alkynyl groups, respectively.
- alkylamino and dialkylarnino
- dialkylarnino refer to -NH(alkyl) and -NH(alkyl) 2 radicals respectively.
- aralkylarnino refers to a -NH(aralkyl) radical.
- alkoxy refers to an -O-alkyl radical
- cycloalkoxy and aralkoxy refer to an - O-cycloalkyl and O-aralkyl radicals respectively.
- sioxy refers to a R 3 SiO- radical.
- alkylene refers to a divalent alkyl ⁇ i.e., -R-), e.g., -CH 2 -, -CH 2 CH 2 -, and -
- alkylenedioxo refers to a divalent species of the structure -O-R-O-, in which R represents an alkylene.
- aryl refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, wherein any ring atom can be substituted. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, anthracenyl, and pyrenyl.
- cycloalkyl as employed herein includes saturated cyclic, bicyclic, tricyclic,or polycyclic hydrocarbon groups having 3 to 12 carbons, wherein any ring atom can be substituted.
- the cycloalkyl groups herein described may also contain fused rings. Fused rings are rings that share a common carbon-carbon bond or a common carbon atom (e.g., spiro-fused rings).
- cycloalkyl moieties include, but are not limited to, cyclohexyl, adamantyl, and norbornyl, and decalin.
- heterocyclyl refers to a nonaromatic 3-10 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom can be substituted.
- the heterocyclyl groups herein described may also contain fused rings.
- Fused rings are rings that share a common carbon-carbon bond or a common carbon atom (e.g., spiro-fused rings).
- heterocyclyl include, but are not limited to tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino, pyrrolinyl and pyrrolidinyl.
- cycloalkenyl as employed herein includes partially unsaturated, nonaromatic, cyclic, bicyclic, tricyclic,or polycyclic hydrocarbon groups having 5 to 12 carbons, preferably 5 to 8 carbons, wherein any ring atom can be substituted.
- the cycloalkenyl groups herein described may also contain fused rings. Fused rings are rings that share a common carbon- carbon bond or a common carbon atom (e.g., spiro-fused rings).
- Examples of cycloalkenyl moieties include, but are not limited to cyclohexenyl, cyclohexadienyl, or norbornenyl.
- heterocycloalkenyl refers to a partially saturated, nonaromatic 5-10 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom can be substituted.
- the heterocycloalkenyl groups herein described may also contain fused rings.
- Fused rings are rings that share a common carbon-carbon bond or a common carbon atom (e.g., spiro-fused rings).
- heterocycloalkenyl include but are not limited to tetrahydropyridyl and dihydropyran.
- heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom can be substituted.
- the heteroaryl groups herein described may also contain fused rings that share a common carbon-carbon bond.
- oxo refers to an oxygen atom, which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur.
- acyl refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted by substituents.
- substituted refers to a group “substituted” on an alkyl, cycloalkyl, alkenyl, alkynyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl, or heteroaryl group at any atom of that group.
- Suitable substituents include, without limitation, alkyl, alkenyl, alkynyl, alkoxy, halo, hydroxy, cyano, nitro, amino, SO 3 H, sulfate, phosphate, perfluoroalkyl, perfluoroalkoxy, methylenedioxy, ethylenedioxy, carboxyl, oxo, thioxo, imino (alkyl, aryl, aralkyl), S(O) n alkyl (where n is 0-2), S(O) n aryl (where n is 0-2), S(O) n heteroaryl (where n is 0-2), S(O) n heterocyclyl (where n is 0-2), amine (mono-, di-, alkyl, cycloalkyl, aralkyl, heteroaralkyl, and combinations thereof), ester (alkyl, aralkyl, heteroaralkyl), amide (mono
- adeninyl, cytosinyl, guaninyl, thyminyl, and uracilyl refer to radicals of adenine, cytosine, guanine, thymine, and uracil.
- a “protected” moiety refers to a reactive functional group, e.g., a hydroxyl group or an amino group, or a class of molecules, e.g., sugars, having one or more functional groups, in which the reactivity of the functional group is temporarily blocked by the presence of an attached protecting group.
- Protecting groups useful for the monomers and methods described herein can be found, e.g., in Greene, T. W., Protective Groups in Organic Synthesis (John Wiley and Sons: New York), 1981, which is hereby incorporated by reference.
- oligonucleotide agent e.g., a conjugated oligonucleotide agent, containing a preferred, but nonlimiting ligand-conjugated monomer subunit is presented as formula (II) below and in the scheme in FIG. 1.
- the carrier also referred to in some embodiments as a "linker”
- the ligand can be directly attached (e.g., conjugated) to the carrier or indirectly attached (e.g., conjugated) to the carrier by an intervening tether (e.g., an acyclic chain of one or more atoms; or a nucleobase, e.g., a naturally occurring nucleobase optionally having one or more chemical modifications, e.g., an unusual base; or a universal base).
- the carrier therefore also includes a "ligand or tethering attachment point" for the ligand and tether/tethered ligand, respectively.
- the ligand-conjugated monomer subunit may be the 5 ' or 3' terminal subunit of the RNA molecule, i.e., one of the two "W” groups may be a hydroxyl group, and the other "W” group may be a chain of two or more unmodified or modified ribonucleotides.
- the ligand-conjugated monomer subunit may occupy an internal position, and both "W” groups may be one or more unmodified or modified ribonucleotides.
- More than one ligand-conjugated monomer subunit may be present in a RNA molecule, e.g., an oligonucleotide agent.
- Preferred positions for inclusion of a tethered ligand-conjugated monomer subunit e.g., one in which a lipophilic moiety, e.g., cholesterol, is tethered to the carrier are at the 3' terminus, the 5' terminus, or at an internal position.
- the modified RNA molecule of formula (JI) can be obtained using oligonucleotide synthetic methods known in the art.
- the modified RNA molecule of formula (II) can be prepared by incorporating one or more of the corresponding monomer compounds (see, e.g., A, B, and C below and in the scheme in FIG. 1) into a growing strand, utilizing, e.g., phosphoramidite or H-phosphonate coupling strategies.
- the monomers e.g., a ligand-conjugated monomers, generally include two differently functionalized hydroxyl groups (OFG 1 and OFG 2 ), which are linked to the carrier molecule (see A below and in FIG.
- hydroxyl group means that the hydroxyl proton has been replaced by another substituent.
- one hydroxyl group (OFG 1 ) on the carrier is functionalized with a protecting group (PG).
- the other hydroxyl group (OFG 2 ) can be functionalized with either (1) a liquid or solid phase synthesis support reagent (solid circle) directly or indirectly through a linker, L, as in B, or (2) a phosphorus- containing moiety, e.g., a phosphoramidite as in C.
- the tethering attachment point may be connected to a hydrogen atom, a suitable protecting group, a tether, or a tethered ligand at the time that the monomer is incorporated into the growing strand (see variable "R" in A below).
- the tethered ligand can be, but need not be attached to the monomer at the time that the monomer is incorporated into the growing strand.
- the tether, the ligand or the tethered ligand may be linked to a "precursor" ligand-conjugated monomer subunit after a "precursor” ligand-conjugated monomer subunit has been incorporated into the strand.
- the wavy line used below refers to a connection, and can represent a direct bond between the moiety and the attachment point or a tethering molecule which is interposed between the moiety and the attachment point.
- Directly tethered means the moiety is bound directly to the attachment point.
- Indirectly tethered means that there is a tether molecule interposed between the attachment point and the moiety.
- the (OFG 1 ) protecting group may be selected as desired, e.g., from T. W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991).
- the protecting group is preferably stable under amidite synthesis conditions, storage conditions, and oligonucleotide synthesis conditions.
- Hydroxyl groups, -OH are nucleophilic groups (i.e., Lewis bases), which react through the oxygen with electrophiles (i.e., Lewis acids).
- Hydroxyl groups in which the hydrogen has been replaced with a protecting group are essentially unreactive as nucleophiles in displacement reactions.
- a protecting group e.g., a triarylmethyl group or a trialkylsilyl group
- the protected hydroxyl group is useful in preventing e.g., homocoupling of compounds exemplified by structure C during oligonucleotide synthesis.
- a preferred protecting group is the dimethoxytrityl group.
- a preferred protecting group is a silicon-based protecting group having the formula below:
- X5', X5", and X5'" can be selected from substituted or unsubstituted alkyl, cycloalkyl, aryl, araklyl, heteroaryl, alkoxy, cycloalkoxy, aralkoxy, aryloxy, heteroaryloxy, or siloxy (i.e., R 3 SiO-, the three "R” groups can be any combination of the above listed groups).
- X may all be the same or different; also contemplated is a combination in which two of X , X 5 , and X 5 are identical and the third is different.
- X 5 , X 5 , and X 5 include those that result in OFG 1 groups that meet the deprotection and stability criteria delineated below.
- the group is preferably stable under amidite synthesis conditions, storage conditions, and oligonucleotide synthesis conditions. Rapid removal, i.e., less than one minute, of the silyl group from e.g., a support- bound oligonucleotide is desirable because it can reduce synthesis times and thereby reduce exposure timeof the growing oligonucleotide chain to the reagents. Oligonucleotide synthesis can be improved if the silyl protecting group is visible during deprotection, e.g., from the addition of a chromophore silyl substituent.
- silyl protecting groups can be complicated by the competing demands of the essential characteristics of stability and facile removal, and the need to balance these competitive goals. Most substituents that increase stability can also increase the reaction time required for removal of the silyl group, potentially increasing the level of difficulty in removal of the group.
- alkoxy and siloxy substituents to OFG 1 silicon-containing protecting groups increases the susceptibility of the protecting groups to fluoride cleavage of the silylether bonds. Increasing the steric bulk of the substituents preserves stability while not decreasing fluoride lability to an equal extent. An appropriate balance of substituents on the silyl group makes a silyl ether a viable nucleoside protecting group.
- Candidate OFG 1 silicon-containing protecting groups may be tested by exposing a tetrahydrofuran solution of a preferred carrier bearing the candidate OFG 1 group to five molar equivalents of tetrahydrofuran at room temperature. The reaction time may be determined by monitoring the disappearance of the starting material by thin layer chromatography.
- the OFG 2 in B includes a linker, e.g., a relatively long organic linker, connected to a soluble or insoluble support reagent
- a linker e.g., a relatively long organic linker
- solution or solid phase synthesis techniques can be employed to build up a chain of natural and/or modified ribonucleotides once OFG 1 is deprotected and free to react as a nucleophile with another nucleoside or monomer containing an electrophilic group (e.g., an amidite group).
- a natural or modified ribonucleotide or oligoribonucleotide chain can be coupled to monomer C via an amidite group or H- phosphonate group at OFG 2 .
- OFG 1 can be deblocked, and the restored nucleophilic hydroxyl group can react with another nucleoside or monomer containing an electrophilic group.
- R' can be substituted or unsubstituted alkyl or alkenyl. In preferred embodiments, R' is methyl, allyl or 2-cyanoethyl.
- R" may a C 1 -C 10 alkyl group, preferably it is a branched group containing three or more carbons, e.g., isopropyl.
- OFG 2 in B can be hydroxyl functionalized with a linker, which in turn contains a liquid or solid phase synthesis support reagent at the other linker terminus.
- the support reagent can be any support medium that can support the monomers described herein.
- the monomer can be attached to an insoluble support via a linker, L, which allows the monomer (and the growing chain) to be solubilized in the solvent in which the support is placed.
- the solubilized, yet immobilized, monomer can react with reagents in the surrounding solvent; unreacted reagents and soluble by-products can be readily washed away from the solid support to which the monomer or monomer-derived products is attached.
- the monomer can be attached to a soluble support moiety, e.g., polyethylene glycol (PEG) and liquid phase synthesis techniques can be used to build up the chain.
- PEG polyethylene glycol
- Linker and support medium selection is within skill of the art.
- the linker may be -C(O)(CH 2 ) q C(O)-, or -C(O)(CH 2 ) q S-, in which q can be 0, 1, 2, 3, or 4; preferably, it is oxalyl, succinyl or thioglycolyl.
- Standard control pore glass solid phase synthesis supports can not be used in conjunction with fluoride labile 5' silyl protecting groups because the glass is degraded by fluoride with a significant reduction in the amount of full-length product.
- Fluoride-stable polystyrene based supports or PEG are preferred.
- the ligand/tethering attachment point can be any divalent, trivalent, tetravalent, pentavalent or hexavalent atom.
- ligand/tethering attachment point can be a carbon, oxygen, nitrogen or sulfur atom.
- a ligand/tethering attachment point precursor functional group can have a nucleophilic heteroatom, e.g., -SH, -NH 2 , secondary amino, ONH 2 , or NH 2 NH 2 .
- the ligand/tethering attachment point precursor functional group can be an electrophilic moiety, e.g., an aldehyde.
- the ligand/tethering attachment point can be an endocyclic atom (i.e., a constituent atom in the cyclic moiety, e.g., a nitrogenatom) or an exocyclic atom (i.e., an atom or group of atoms attached to a constituent atom in the cyclic moiety).
- the carrier can be any organic molecule containing attachment points for OFG , OFG , and the ligand.
- carrier is a cyclic molecule and may contain heteroatoms (e.g., O, N or S).
- carrier molecules may include aryl (e.g., benzene, biphenyl, etc.), cycloalkyl (e.g., cyclohexane, cis or trans decalin, etc.), or heterocyclyl (piperazine, pyrrolidine, etc.).
- the carrier can be an acyclic moiety, e.g., based on serinol. Any of the above cyclic systems may include substituents in addition to OFG 1 , OFG , and the ligand.
- the carrier molecule is an oxygen containing heterocycle.
- the carrier is a ribose sugar as shown in structure LCM-I.
- the ligand-conjugated monomer is a nucleoside.
- B represents a nucleobase, e.g., a naturally occurring nucleobase optionally having one or more chemical modifications, e.g., and unusual base; or a universal base.
- an "unusual" nucleobase can include any one of the following: 2-methyladeninyl,
- a universal base can form base pairs with each of the natural DNA/RNA bases, exhibiting relatively little discrimination between them.
- the universal bases are non- hydrogen bonding, hydrophobic, aromatic moieties which can stabilize e.g., duplex RNA or RNA-like molecules, via stacking interactions.
- a universal base can also include hydrogen bonding substituents.
- a “universal base” can include anthracenes, pyrenes or any one of the following:
- B can form part of a tether that connects a ligand to the carrier.
- the double bond is trans
- the ligand is a substituted or unsubstituted cholesterolyl radical ⁇ e.g., attached through the D-ring side chain or the C-3 hydroxyl); an aralkyl moiety having at least one sterogenic center and at least one substituent on the aryl portion of the aralkyl group; or a nucleobase.
- B in the tether described above, is uracilyl or a universal base, e.g., an aryl moiety, e.g., phenyl, optionally having additional substituents, e.g., one or more fluoro groups. B can be substituted at any atom with the remainder of the tether.
- X 2 can include "oxy" or “deoxy” substituents in place of the 2'-OH or be a ligand or a tethered ligand.
- Amine protecting groups can include formyl, amido, benzyl, allyl, etc.
- Preferred orthoesters have the general formula J.
- the groups R 31 and R 32 may be the same or different and can be any combination of the groups listed in FIG. 2B.
- a preferred orthoester is the "ACE" group, shown below as structure K.
- X 3 is as described for OFG 2 above.
- PG can be a triarylmethyl group (e.g., a dimethoxytrityl group) or Si(X )(X )(X ) in which (X 5 ),(X 5 ), and (X 5 ) are as described elsewhere.
- a triarylmethyl group e.g., a dimethoxytrityl group
- Cyclic sugar replacement-based monomers e.g., sugar replacement-based ligand- conjugated monomers, are also referred to herein as sugar replacement monomer subunit
- Preferred carriers have the general formula (LCM-2) provided below, (hi that structure preferred backbone attachment points can be chosen from R or R ; R or R 4 ; or R 9 and R 10 if Y is CR 9 R 10 (two positions are chosen to give two backbone attachment points, e.g., R 1 and R 4 , or R 4 and R 9 ).
- Preferred tethering attachment points include R 7 ; R 5 or R when X is CH 2 .
- the carriers are described below as an entity, which can be incorporated into a strand.
- the structures also encompass the situations wherein one (in the case of a terminal position) or two (in the case of an internal position) of the attachment points, e.g., R 1 or R 2 ; R 3 or R 4 ; or R 9 or R 10 (when Y is CR 9 R 10 ), is connected to the phosphate, or modified phosphate, e.g., sulfur containing, backbone.
- one of the above-named R groups can be -CH 2 -, wherein one bond is connected to the carrier and one to a backbone atom, e.g., a linking oxygen or a central phosphorus atom.
- X is N(CO)R 7 , NR 7 or CH 2 ;
- Y is NR 8 , 0, S 5 CR 9 R 10 ;
- Z is CR 11 R 12 or absent;
- R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , or (CH 2 ) n OR b , provided that at least two of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 are OR a and/or (CH 2 ) n OR b ;
- R 5 , R 6 , R 11 , and R 12 is, independently, a ligand, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ;
- R 7 can be a ligand, e.g., R 7 can be R d , or R 7 can be a ligand tethered indirectly to the carrier, e.g., through a tethering moiety, e.g., C 1 -C 20 alkyl substituted withNR c R d ; or C 1 -C 20 alkyl substituted with NHC(0)R d ;
- R 8 is H or C 1 -C 6 alkyl;
- R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;
- R 14 is NR c R 7 ;
- R 15 is C 1 -C 6 alkyl optionally substituted with cyano, or C 2 -C 6 alkenyl;
- R 16 is C 1 -C 10 alkyl;
- R 17 is a liquid or solid phase support reagent
- L is -C(O)(CH 2 ) q C(O)-, or -C(O)(CH 2 ) q S-
- R a is a protecting group, e.g., CAr 3 ; (e.g., a dimethoxytrityl group) or Si(X 5' )(X 5 )(X 5 ) in which (X 5 ),(X 5 ), and (X 5 ) are as described elsewhere.
- R b is P(O)(O-)H, P(OR 15 )N(R 16 ) 2 or L-R 17 ;
- R c is H or d-C 6 alkyl;
- R d is H or a ligand;
- Each Ar is, independently, C 6 -C 10 aryl optionally substituted with C 1 -C 4 alkoxy; n is 1-4; and q is 0-4.
- the carrier may be based on the pyrroline ring system or the 4- hydroxyproline ring system, e.g., X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent (D).
- OFG 1 is preferably attached to a primary carbon, e.g., an exocyclic alkylene
- -CH 2 OFG 1 in D is connected to one of the carbons in the five-membered ring
- OFG 2 is preferably attached directly to one of the carbons in the five- membered ring (-OFG 2 in D).
- -CH 2 OFG 1 may be attached to C- 2 and OFG 2 may be attached to C-3; or -CH 2 OFG 1 maybe attached to C-3 and OFG 2 maybe attached to C-4.
- CH 2 OFG 1 and OFG 2 may be geminally substituted to one of the above-referenced carbons.
- -CH 2 OFG 1 may be attached to C-2 and OFG 2 may be attached to C-4.
- the pyrroline- and 4-hydroxyproline- based monomers may therefore contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring.
- linkages e.g., carbon-carbon bonds
- CH 2 OFG 1 and OFG 2 may be cis or trans with respect to one another in any of the pairings delineated above Accordingly, all cis/trans isomers are expressly included.
- the monomers may also contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures.
- the tethering attachment point is preferably nitrogen.
- Preferred examples of carrier D include the following:
- the carrier may be based on the piperidine ring system (E), e.g., X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is CR 11 R 12 .
- OFG 1 is preferably
- OFG 2 is preferably attached directly to one of the carbons in the six-membered ring (-OFG in E).
- -(CH 2 ) I iOFG 1 and OFG 2 may be disposed in a geminal manner on the ring, i.e., both groups may be attached to the same carbon, e.g., at C-2, C-3, or C-4.
- -(CH 2 ) I iOFG 1 and OFG 2 may be disposed in a geminal manner on the ring, i.e., both groups may be attached to the same carbon, e.g., at C-2, C-3, or C-4.
- -(CH 2 ) I iOFG 1 and OFG 2 may be disposed in a geminal manner on the ring, i.e., both groups may be attached to the same carbon, e.g., at C-2, C-3, or C-4.
- -(CH 2 ) I iOFG 1 and OFG 2 may be disposed
- (CH ⁇ n OFG 1 and OFG 2 may be disposed in a vicinal manner on the ring, i.e., both groups may be attached to adjacent ring carbon atoms, e.g., -(CH 2 ) H OFG 1 may be attached to C-2 and OFG 2 may be attached to C-3; -(CH ⁇ n OFG 1 may be attached to C-3 and OFG 2 may be attached to C-2; may be attached to C-4 and OFG 2 may be attached to C-3.
- the piperidine-based monomers may therefore contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring.
- -(CH 2 ) n OFG and OFG 2 may be cis or trans with respect to one another in any of the pairings delineated above. Accordingly, all cis/trans isomers are expressly included.
- the monomers may also contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of the monomers are expressly included (e.g., the centers bearing CH 2 OFG and OFG can both have the R configuration; or both have the S configuration; or one center can have the R configuration and the other center can have the S configuration and vice versa).
- the tethering attachment point is preferably nitrogen.
- the carrier may be based on the piperazine ring system (F), e.g., X is N(CO)R 7 or NR 7 , Y is NR 8 , and Z is CR 11 R 12 , or the morpholine ring system (G), e.g., X is N(CO)R 7 or NR 7 , Y is O, and Z is CR 11 R 12 .
- F piperazine ring system
- G e.g., X is N(CO)R 7 or NR 7
- Y is O
- Z is CR 11 R 12 .
- OFG 1 is preferably
- a primary carbon e.g., an exocyclic alkylene group, e.g., a methylene group
- OFG 2 is preferably attached directly to one of the carbons in the six-membered rings (-OFG 2 in F or G).
- -CH 2 OFG 1 may be attached to C-2 and OFG 2 may be attached to C-3; or vice versa.
- CH 2 OFG 1 and OFG 2 may be geminally substituted to one of the above-referenced carbons.
- the piperazine- and morpholine-based monomers may therefore contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring.
- linkages e.g., carbon-carbon bonds
- CH 2 OFG 1 and OFG 2 may be cis or trans with respect to one another in any of the pairings delineated above. Accordingly, all cis/trans isomers are expressly included.
- the monomers may also contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures.
- AU such isomeric forms of the monomers are expressly included (e.g., the centers bearing CH 2 OFG 1 and OFG 2 can both have the R configuration; or both have the S configuration; or one center can have the R configuration and the other center can have the S configuration and vice versa).
- R'" can be, e.g., C 1 -C 6 alkyl, preferably CH 3 .
- the tethering attachment point is preferably nitrogen in both F and G.
- OFG 1 is preferably attached to a primary carbon
- OFG 2 is preferably attached directly to one of C-2, C-3, C-4, or C-5 (-OFG 2 in H).
- -(CHi) n OFG 1 and OFG 2 may be disposed in a geminal manner on the ring, i.e., both groups may be attached to the same carbon, e.g., at C-2, C-3, C-4, or C-5.
- -(CHi) n OFG 1 and OFG 2 may be disposed in a vicinal manner on the ring, i.e., both groups may be attached to adjacent ring carbon atoms, e.g., -(CH ⁇ n OFG 1 may be attached to C-2 and OFG 2 may be attached to C-3; -(CH ⁇ n OFG 1 may be attached to C-3 and OFG 2 may be attached to C-2; -(CH ⁇ OFG 1 may be attached to C-3 and OFG 2 may be attached to C-4; or - (CH ⁇ n OFG 1 may be attached to C-4 and OFG 2 may be attached to C-3 ; -(CH ⁇ n OFG 1 may be attached to C-4 and OFG 2 may be attached to C-5; or -(CH ⁇ n OFG 1 may be attached to C-5 and OFG 2 may be attached to C-4.
- the decalin or indane-based monomers may therefore contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring.
- linkages e.g., carbon-carbon bonds
- OFG and OFG may be cis or trans with respect to one another in any of the pairings delineated above. Accordingly, all cis/trans isomers are expressly included.
- the monomers may also contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures.
- the centers bearing CH 2 OFG 1 and OFG 2 can both have the R configuration; or both have the S configuration; or one center can have the R configuration and the other center can have the S configuration and vice versa).
- the substituents at C-I and C-6 are trans with respect to one another.
- the tethering attachment point is preferably C-6 or C-7.
- OFG 2 may be cis or trans with respect to one another. Accordingly, all cis/trans isomers are expressly included.
- the monomers may also contain one or more asymmetric centers
- the tethering attachment point is preferably nitrogen.
- Representative cyclic, sugar replacement-based carriers are shown in FIG. 3.
- Acyclic sugar replacement-based monomers e.g., sugar replacement-based ligand- conjugated monomers
- SRMS sugar replacement monomer subunit
- Preferred acyclic carriers can have formula LCM-3 or LCM-4 below.
- each of x, y, and z can be, independently of one another, 0, 1, 2, or
- the tertiary carbon when y and z are different, then the tertiary carbon can have either the R or S configuration.
- x is zero and y and z are each 1 in formula LCM- 3(e.g., based on serinol), and y and z are each 1 in formula LCM-3.
- Each of formula LCM-3 or LCM-4 below can optionally be substituted, e.g., with hydroxy, alkoxy, perhaloalkyl.
- a moiety e.g., a ligand may be connected indirectly to the carrier via the intermediacy of an intervening tether.
- Tethers are connected to the carrier at a tethering attachment point (TAP) and may include any C 1 -C 1O o carbon-containing moiety, (e.g. C 1 -C 75 , C 1 - C 5 O, C 1 -C 20 , C 1 -C 10 ; C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , or C 10 ), preferably having at least one nitrogen atom.
- TAP tethering attachment point
- the nitrogen atom forms part of a terminal amino or amido (NHC(O)-) group on the tether, which may serve as a connection point for the ligand.
- Preferred tethers include TAP-(CHANH-; TAP-C(O)(CH 2 VNH-: TAP- NR""(CH 2 VNH-, TAP-C(OV(CH 2 VC(OV; TAP-C(OV(CH 2 V-C(O)O-; TAP-C(OVO-; TAP- C(OV(CH 2 V-NH-C(O)-; TAP-C(O)-(CH 2 V-; TAP-C(O)-NH-; TAP-C(O)-; TAP-(CH 2 V-C(O)-; TAP-(CH 2 V-C(O)O-; TAP-(CH 2 VLOr TAP-(CH 2 V-NH-C(O)-; in which n is 1-20 (e.g., TAP-C(
- R" is C 1 -C 6 alkyl.
- n is 5, 6, or 11.
- the nitrogen may form part of a terminal oxyamino group, e.g., -ONH 2 , or hydrazino group, -NHNH 2 .
- the tether may optionally be substituted, e.g., with hydroxy, alkoxy, perhaloalkyl, and/or optionally inserted with one or more additional heteroatoms, e.g., N, O, or S.
- Preferred tethered ligands may include, e.g., TAP; (CHANH(LIGAND): TAP-C(O)(CHANH(LIGAND): TAP-NR' ' "(CHANHfLIGAND); TAP-(CHAONH(LIGAND); TAP-C(O)(CHAONH(LIGAND); TAP- NR' ' "(CHAONH(LIGAND); TAP-(CHANHNH Z (LIGAND), TAP- C(O)(CH 7 Ur ⁇ NH 7 (LIGAND); TAP-NR' ' "(CHANHNH 7 (LIGAND): TAP-C(O)-(CHA- C(O)(LIGAND): TAP-C(O)-(CH 7 VC(O)O(LIGAND): TAP-C(O)-O(LIGAND): TAP-C(O)- (CHA-NH-C(O)(LIGAND): TAP-C(O)-(CHA(
- amino terminated tethers e.g., NH 2 , ONH 2 , NH 2 NH 2
- amino terminated tethers e.g., NH 2 , ONH 2 , NH 2 NH 2
- the olefin can be a Diels- Alder diene or dienophile.
- the tether may optionally be substituted, e.g., with hydroxy, alkoxy, perhaloalkyl, and/or optionally inserted with one or more additional heteroatoms, e.g., N, O, or S.
- the double bond can be as or trans or E or Z.
- the tether may include an electrophilic moiety, preferably at the terminal position of the tether.
- Preferred electrophilic moieties include, e.g., an aldehyde, alkyl halide, mesylate, tosylate, nosylate, or brosylate, or an activated carboxylic acid ester, e.g. an NHS ester, or a pentafiuorophenyl ester.
- Preferred tethers include TAP- (CHACHO; TAP-C(O)(CH 2 )XHO; or TAP-NR" "(CHACHO, in which n is 1-6 and R"" is C 1 -C 6 alkyl; or TAP-(CHAC(0)0NHS; TAP-C(O)(CH 2 )X(O)ONHS: or TAP-NR""(CH 7 ) X(O)ONHS, in which n is 1-6 and R”" is C 1 -C 6 alkyl; TAP-(CHAC(O)OC 6 F,; TAP- C(O)(CH 7 )X(O) OCgF 5 ; or TAP-NR" "(CHA C(O) OC 6 Fs, in which n is 1-11 and R"" is C 1 - C 6 alkyl; or -(CH 7 ICH 7 LG: TAP-C(O)(CHACH 7 LG; or TAP-NR' ' ' ' ' (
- Tethering can be carried out by coupling a nucleophilic group of a ligand, e.g., a thiol or amino group with an electrophilic group on the tether.
- a nucleophilic group of a ligand e.g., a thiol or amino group
- electrophilic group on the tether it can be desirable for the ligand-conjugated monomer or a ligand- conjugated monomer to include a phthalimido group (K) at the terminal position of the tether.
- K phthalimido group
- other protected amino groups can be at the terminal position of the tether, e.g., alloc, monomethoxy trityl (MMT), trifluoroacetyl, Fmoc, or aryl sulfonyl (e.g., the aryl portion can be oz'tAo-nitrophenyl or ortho, p ⁇ m-dinitrophenyl).
- MMT monomethoxy trityl
- aryl sulfonyl e.g., the aryl portion can be oz'tAo-nitrophenyl or ortho, p ⁇ m-dinitrophenyl.
- Entities can be coupled at other points to an oligonucleotide agent.
- a ligand tethered to an oligonucleotide agent can have a favorable effect on the agent.
- the ligand can improve stability, hybridization thermodynamics with a target nucleic acid, targeting to a particular tissue or cell- type, or cell permeability, e.g., by an endocytosis-dependent or -independent mechanism.
- Ligands and associated modifications can also increase sequence specificity and consequently decrease off-site targeting.
- a tethered ligand can include one or more modified bases or sugars that can function as intercalators. These are preferably located in an internal region, such as in a bulge of a miRNA/target duplex.
- the intercalator can be an aromatic, e.g., apolycyclic aromatic or heterocyclic aromatic compound.
- a polycyclic intercalator can have stacking capabilities, and can include systems with 2, 3, or 4 fused rings.
- the universal bases described herein can be included on a ligand.
- the ligand can include a cleaving group that contributes to target gene inhibition by cleavage of the target nucleic acid.
- the cleaving group can be, for example, a bleomycin (e.g., bleomycin- A5, bleomycin- A2, or bleomycin-B2), pyrene, phenanthroline (e.g., O-phenanthroline), a polyamine, a tripeptide (e.g., lys-tyr-lys tripeptide), or metal ion chelating group.
- a bleomycin e.g., bleomycin- A5, bleomycin- A2, or bleomycin-B2
- phenanthroline e.g., O-phenanthroline
- polyamine e.g., a tripeptide (e.g., lys-tyr-lys tripeptide), or metal ion chelating group.
- the metal ion chelating group can include, e.g., an Lu(III) or EU(III) macrocyclic complex, a Zn(II) 2,9-dimethylphenanthroline derivative, a Cu(II) terpyridine, or acridine, which can promote the selective cleavage of target RNA at the site of the bulge by free metal ions, such as Lu(DT).
- a peptide ligand can be tethered to a rniRNA to promote cleavage of the target RNA, e.g., at the bulge region.
- l,8-dmiethyl ⁇ l,3,6,8,10,13- hexaazacyclotetradecane can be conjugated to a peptide (e.g., by an amino acid derivative) to promote target RNA cleavage.
- a tethered ligand can be an aminoglycoside ligand, which can cause an oligonucleotide agent to have improved hybridization properties or improved sequence specificity.
- exemplary aminoglycosides include glycosylated polylysine, galactosylated polylysine, neomycin B, tobramycin, kanamycin A, and acridine conjugates of aminoglycosides, such as Neo-N-acridine, Neo-S-acridine, Neo-C-acridine, Tobra-N-acridine, and KanaA-N-acridine.
- Use of an acridine analog can increase sequence specificity.
- neomycin B has a high affinity for RNA as compared to DNA, but low sequence-specificity.
- An acridine analog, neo-S-acridine has an increased affinity for the HIV Rev-response element (RRE).
- the guanidine analog (the guanidinoglycoside) of an aminoglycoside ligand is tethered to an oligonucleotide agent.
- the amine group on the amino acid is exchanged for a guanidine group.
- Attachment of a guanidine analog can enhance cell permeability of an oligonucleotide agent, e.g., an oligonucleotide agent targeting an miRNA or pre-miRNA..
- a tethered ligand can be a poly-arginine peptide, peptoid or peptidomimetic, which can enhance the cellular uptake of an oligonucleotide agent.
- Preferred moieties are ligands, which are coupled, preferably covalently, either directly or indirectly via an intervening tether, to the ligand-conjugated carrier.
- the ligand is attached to the carrier via an intervening tether.
- the ligand or tethered ligand may be present on the monomer when the monomer is incorporated into the growing strand.
- the ligand may be incorporated into a "precursor” a ligand-conjugated monomer subunit after a "precursor” a ligand-conjugated monomer has been incorporated into the growing strand.
- a monomer having, e.g., an amino- terminated tether, e.g., TAP-(CH 2 ) n NH 2 maybe incorporated into a growing oligonucleotide strand, hi a subsequent operation, i.e., after incorporation of the precursor monomer into the strand, a ligand having an electrophilic group, e.g., a pentafluorophenyl ester or aldehyde group, can subsequently be attached to the precursor monomer subunit by coupling the electrophilic group of the ligand with the terminal nucleophilic group of the precursor monomer subunit tether.
- an amino- terminated tether e.g., TAP-(CH 2 ) n NH 2
- a ligand alters the distribution, targeting or lifetime of an oligonucleotide agent into which it is incorporated.
- a ligand provides an enhanced affinity for a selected target, e.g, molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand.
- Preferred ligands can improve transport, hybridization, and specificity properties and may also improve nuclease resistance of the resultant natural or modified oligoribonucleotide, or a polymeric molecule comprising any combination of monomers described herein and/or natural or modified ribonucleotides.
- Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake; diagnostic compounds or reporter groups e.g., for monitoring distribution; cross-linking agents; nuclease-resistance conferring moieties; and natural or unusual nucleobases.
- Lipophiles examples include lipophiles, lipids, steroids (e.g., uvaol, hecigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol derivatized lithocholic acid), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal), carbohydrates, proteins, protein binding agents, integrin targeting molecules,polycationics, peptides, polyamines, and peptide mimics.
- steroids e.g., uvaol, hecigenin, diosgenin
- terpenes e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol derivatized lithocholic acid
- vitamins e.g., folic acid, vitamin A, biotin
- Ligands can include a naturally occurring substance, (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); amino acid, or a lipid.
- HSA human serum albumin
- LDL low-density lipoprotein
- globulin carbohydrate
- carbohydrate e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid
- amino acid or a lipid.
- the ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid.
- polyamino acids examples include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L- lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2- hydroxy ⁇ ropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine.
- PLL polylysine
- poly L-aspartic acid poly L-glutamic acid
- styrene-maleic acid anhydride copolymer poly(L- lactide-co-glycolied) copolymer
- divinyl ether-maleic anhydride copolymer divinyl
- polyamines include: polyethylenirnine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.
- Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell.
- a targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl- galactosamine, N-acetyl-glucosamine, multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B 12, biotin, or an RGD peptide or RGD peptide mimetic.
- ligands include dyes, intercalating agents (e.g. acridines and substituted acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine, phenanthroline, pyrenes), lys-tyr-lys tripeptide, aminoglycosides, guanidium aminoglycodies, artificial endonucleases (e.g.
- intercalating agents e.g. acridines and substituted acridines
- cross-linkers e.g. psoralene, mitomycin C
- porphyrins TPPC4, texaphyrin, Sapphyrin
- polycyclic aromatic hydrocarbons e.g., phenazine, dihydrophenazine, phen
- EDTA lipophilic molecules
- cholic acid cholanic acid, lithocholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone
- glycerol e.g., esters (e.g., mono, bis, or tris fatty acid esters, e.g., C 10 , C 11 , C 12 , C 13 ,C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , or C 20 fatty acids
- ethers thereof e.g., C 10 , C 11 , C 12 , C 13 ,C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , or C 20 alkyl
- biotin e.g., aspirin, naproxen, vitamin E, folic acid
- transport/absorption facilitators e.g., aspirin, naproxen, vitamin E, folic acid
- synthetic ribonucleases e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.
- Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell.
- Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl- glucosamine multivalent mannose, or multivalent fucose.
- the ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF- ⁇ B.
- the ligand can be a substance, e.g, a drug, which can increase the uptake of the oligonucleotide agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments.
- the drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculinA, phalloidin, swinholide A, indanocine, or myoservin.
- the ligand can increase the uptake of the oligonucleotide agent into the cell by activating an inflammatory response, for example.
- exemplary ligands that would have such an effect include tumor necrosis factor alpha (TNFalpha), interleukin-1 beta, or gamma interferon.
- TNFalpha tumor necrosis factor alpha
- interleukin-1 beta interleukin-1 beta
- gamma interferon e.g., tumor necrosis factor alpha (TNFalpha), interleukin-1 beta, or gamma interferon.
- the ligand is a lipid or lipid-based molecule.
- Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA).
- HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body.
- the target tissue can be the liver, including parenchymal cells of the liver.
- Other molecules that can bind HSA can also be used as ligands.
- ligands For example, neproxin or aspirin can be used.
- a lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, e.g., HSA.
- a lipid based ligand can be used to modulate, e.g., control the binding of the conjugate to a target tissue.
- a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body.
- a lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.
- the lipid based ligand binds HSA.
- a lipid-based ligand can bind HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.
- the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney.
- Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.
- the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.
- Exemplary vitamins include vitamin A, E, and K.
- Other exemplary vitamins include are B vitamin, e.g., folic acid, B 12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells.
- the ligand is a cell-permeation agent, preferably a helical cell- permeation agent.
- the agent is amphipathic.
- An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids.
- the helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.
- RGD containing peptides and peptidomimetics can target cancer cells, in particular cells that exhibit an ⁇ v ⁇ 3 integrin.
- RGD one can use other moieties that target the ⁇ v - ⁇ 3 integrin ligand. Generally, such ligands can be used to control proliferating cells and angiogeneis.
- Preferred conjugates of this type include an oligonucleotide agent that targets PECAM-I, VEGF, or other cancer gene, e.g., a cancer gene described herein.
- the oligonucleotide agents of the invention are particularly useful when targeted to the liver.
- a single stranded oligonucleotide agent featured in the invention can target an miRNA enriched in the liver, and the oligonucleotide agent can include a ligand for enhanced delivery to the liver.
- An oligonucleotide agent can be targeted to the liver by incorporation of a monomer derivatized with a ligand which targets to the liver.
- a liver-targeting agent can be a lipophilic moiety.
- Preferred lipophilic moieties include lipid, cholesterols, oleyl, retinyl, or cholesteryl residues.
- Other lipophilic moieties that can function as liver-targeting agents include cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, 03- (oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.
- An oligonucleotide agent can also be targeted to the liver by association with a low- density lipoprotein (LDL), such as lactosylated LDL.
- LDL low- density lipoprotein
- Polymeric carriers complexed with sugar residues can also function to target oligonucleotide agents to the liver.
- a targeting agent that incorporates a sugar, e.g., galactose and/or analogues thereof, is particularly useful. These agents target, in particular, the parenchymal cells of the liver (see Table 2).
- a targeting moiety can include more than one or preferably two or three galactose moieties, spaced about 15 angstroms from each other.
- the targeting moiety can alternatively be lactose (e.g., three lactose moieties), which is glucose coupled to a galactose.
- the targeting moiety can also be N-Acetyl-Galactosamine, N-Ac-Glucosamine.
- a mannose or mannose-6-phosphate targeting moiety can be used for macrophage targeting.
- the ligand can be a peptide or peptidomimetic.
- a peptidomimetic also referred to herein as an oligopeptidomimetic is a molecule capable of folding into a defined three- dimensional structure similar to a natural peptide.
- the attachment of peptide and peptidomimetics to oligonucleotide agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption.
- the peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long (see Table 2, for example).
- a peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe).
- the peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide.
- the peptide moiety can include a hydrophobic membrane translocation sequence (MTS).
- An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 16).
- An RFGF analogue e.g., amino acid sequence AALLPVLLAAP (SEQ DD NO: 17)
- a hydrophobic MTS can also be a targeting moiety.
- the peptide moiety can be a "delivery" peptide, which can carry large polar molecules including peptides, oligonucleotides, and proteins across cell membranes.
- sequences from the HIV Tat protein GRKKRRQRRRPPQ (SEQ ID NO: 18)
- the Drosophila Antennapedia protein RQ ⁇ KIWFQNRRMKWKK (SEQ ID NO:19) have been found to be capable of functioning as delivery peptides.
- a peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al, Nature, 354:82-84, 1991).
- OBOC one-bead-one-compound
- the peptide or peptidomimetic tethered to an oligonucleotide agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic.
- RGD arginine-glycine-aspartic acid
- a peptide moiety can range in length from about 5 amino acids to about 40 amino acids.
- the peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.
- An RGD peptide moiety can be used to target a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann et al, Cancer Res., 62:5139-43, 2002).
- An RGD peptide can facilitate targeting of an oligonucleotide agent (e.g., an oligonucleotide agent targeting an miRNA or pre-miRNA) to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki et al, Cancer Gene Therapy 8:783-787, 2001).
- the RGD peptide will facilitate targeting of an oligonucleotide agent to the kidney.
- the RGD peptide can be linear or cyclic, and can be modified, e.g., glycosylated or methylated to facilitate targeting to specific tissues.
- a glycosylated RGD peptide can deliver an oligonucleotide agent to a tumor cell expressing OvB 3 (Haubner et al, Jour. Nucl Med., 42:326- 336, 2001).
- RGD containing peptides and peptidomimetics can target cancer cells, in particular cells that exhibit an ⁇ v ⁇ 3 integrin.
- RGD one can use other moieties that target the ⁇ v - ⁇ 3 integrin ligand.
- such ligands can be used to control proliferating cells and angiogeneis.
- Preferred conjugates of this type include an oligonucleotide agent that targets PECAM-I, VEGF, or other cancer gene, e.g., a cancer gene described herein.
- a "cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell.
- a microbial cell- permeating peptide can be, for example, an ⁇ -helical linear peptide (e.g., LL-37 or Ceropin Pl), a disulfide bond-containing peptide (e.g., a -defensin, /3-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin).
- a cell permeation peptide can also include a nuclear localization signal (NLS).
- NLS nuclear localization signal
- a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-I gp41 and the NLS of SV40 large T antigen (Simeoni et ah, Nucl. Acids Res. 31:2717-2724, 2003).
- a targeting peptide tethered to a ligand-conjugated monomer can be an amphipathic ⁇ -helical peptide.
- amphipathic ⁇ -helical peptides include, but are not limited to, cecropins, lycotoxins, paradaxins, buforin, CPF, bombinin-like peptide (BLP), cathelicidins, ceratotoxins, S.
- clava peptides hagfish intestinal antimicrobial peptides (HFIAPs), magainines, brevinins-2, dermaseptins, melittins, pleurocidin, H 2 A peptides, Xenopus peptides, esculentinis- 1 , and caerins.
- HFIAPs hagfish intestinal antimicrobial peptides
- magainines brevinins-2
- dermaseptins melittins
- pleurocidin H 2 A peptides
- Xenopus peptides esculentinis- 1
- caerins a number of factors will preferably be considered to maintain the integrity of helix stability.
- a maximum number of helix stabilization residues will be utilized (e.g., leu, ala, or lys), and a minimum number of helix destabilization residues will be utilized (e.g., proline, or cyclic monomeric units).
- the capping residue will be considered (for example GIy is an exemplary N-capping residue) and/or C-terminal amidation can be used to provide an extra H-bond to stabilize the helix.
- Formation of salt bridges between residues with opposite charges, separated by i ⁇ 3, or i ⁇ 4 positions can provide stability.
- cationic residues such as lysine, arginine, homo-argir ⁇ ne, ornithine or histidine can form salt bridges with the anionic residues glutamate or aspartate.
- Peptide and peptidomimetic ligands include those having naturally occurring or modified peptides, e.g., D or L peptides; ⁇ , ⁇ , or ⁇ peptides; N-methyl peptides; azapeptides; peptides having one or more amide, i.e., peptide, linkages replaced with one or more urea, thiourea, carbamate, or sulfonyl urea linkages; or cyclic peptides.
- the peptide can have a cationic and/or a hydrophobic moiety.
- the ligand can be any of the nucleobases described herein.
- the ligand can be a substituted amine, e.g. dimethylamino.
- the substituted amine can be quaternized, e.g., by protonation or alkylation, rendering it cationic.
- the substituted amine can be at the terminal position of a relatively hydrophobic tether, e.g., alkylene.
- the ligand can be one of the following triterpenes:
- the ligand can be substituted or unsubstituted cholesterol, or a stereoisomer thereof or one of the following steroids:
- a tethered ligand can contain one or more atoms than the corresponding untethered or uncoupled ligand (e.g., one or more protons of a heteroatom-based functional group or an entire heteroatom-based functional group may be displaced from the uncoupled ligand during coupling of a ligand to a carrier or tether).
- the proton of the 3-hydroxy group of cholesterol can be replaced by a tether (e.g., Chol-3-OH (uncoupled) and Chol-3-O-tether (coupled)) or the entire 3-hydroxy group of cholesterol can be replaced by a sulfur atom (e.g., Chol-3-OH (uncoupled) and Chol-3-S-tether (coupled, e.g., thiocholesterol)).
- a tether e.g., Chol-3-OH (uncoupled) and Chol-3-O-tether (coupled)
- a sulfur atom e.g., Chol-3-OH (uncoupled) and Chol-3-S-tether (coupled, e.g., thiocholesterol).
- RNA Modification Database maintained by Pamela F. Crain, Jef Rozenski and James A. McCloskey; Departments of Medicinal Chemistry and Biochemistry, University of Utah, Salt Lake City, UT 84112, USA.
- the 5' silyl protecting group can be used in conjunction with acid labile orthoesters at the T position of ribonucleosides to synthesize oligonucleotides via phosphoramidite chemistry. Final deprotection conditions are known not to significantly degrade RNA products. Functional groups on the unusual and universal bases are blocked during oligonucleotide synthesis with protecting groups that are compatible with the operations being performed that are described herein. All syntheses can be conducted in any automated or manual synthesizer on large, medium, or small scale. The syntheses may also be carried out in multiple well plates or glass slides.
- the 5'-O-silyl group can be removed via exposure to fluoride ions, which can include any source of fluoride ion, e.g., those salts containing fluoride ion paired with inorganic counterions e.g., cesium fluoride and potassium fluoride or those salts containing fluoride ion paired with an organic counterion, e.g., a tetraalkylammonium fluoride.
- a crown ether catalyst can be utilized in combination with the inorganic fluoride in the deprotection reaction.
- Preferred fluoride ion source are tetrabutylammonium fluoride or aminehydrofluorides (e.g., combining aqueous HF with triethylamine in a dipolar aprotic solvent, e.g., dimethylformarnide).
- the choice of protecting groups for use on the phosphite triesters and phosphotriesters can alter the stability of the triesters towards fluoride. Methyl protection of the phosphotriester or phosphitetriester can stabilize the linkage against fluoride ions and improve process yields.
- ribonucleosides have a reactive T hydroxyl substituent, it can be desirable to protect the reactive 2' position in RNA with a protecting group that is compatible with a 5'-O- silyl protecting group, e.g. one stable to fluoride.
- Orthoesters meet this criterion and can be readily removed in a final acid deprotection step that can result in minimal RNA degradation.
- Tetrazole catalysts can be used in the standard phosphoramidite coupling reaction.
- Preferred catalysts include e.g. tetrazole, S-ethyl-tetrazole, p-nitrophenyltetrazole.
- Nucleosides are suitably protected and functionalized for use in solid-phase or solution-phase synthesis of RNA oligonucleotides.
- the 2'-hydroxyl group in a ribonucleotide can be modified using a tris orthoester reagent.
- the 2'-hydroxyl can be modified to yield a 2'-O-orthoester nucleoside by reacting the ribonucleoside with the tris orthoester reagent in the presence of an acidic catalyst, e.g., pyridinium p-toluene sulfonate. This reaction is known to those skilled in the art.
- the product can then be subjected to further protecting group reactions (e.g., 5'-O-silylation) and functionalizations (e.g., 3'-O- phosphitylation) to produce a desired reagent (e.g., nucleoside phosphoramidite) for incorporation within an oligonucleotide or polymer by reactions known to those skilled in the art.
- further protecting group reactions e.g., 5'-O-silylation
- functionalizations e.g., 3'-O- phosphitylation
- Preferred orthoesters include those comprising ethylene glycol ligands which are protected with acyl or ester protecting groups. Specifically, the preferred acyl group is acetyl.
- the nucleoside reagents may then be used by those skilled in the art to synthesize RNA oligonucleotides on commercially available synthesizer instruments, e.g., Gene Assembler Plus (Pharmacia), 380B (Applied Biosystems). Following synthesis (either solution-phase or solid- phase) of an oligonucleotide or polymer, the product can be subjected to one or more reactions using non-acidic reagents.
- One of these reactions may be strong basic conditions, for example, 40% methylamine in water for 10 minutes at 55°C, which will remove the acyl protecting groups from the ethylene glycol ligands but leave the orthoester moiety attached.
- the resultant orthoester may be left attached when the polymer or oligonucleotide is used in subsequent applications, or it may be removed in a final mildly-acidic reaction, for example, 10 minutes at 55°C in 50 niM acetic acid, pH 3.0, followed by addition of equal volume of 150 mM TRIS buffer for 10 minutes at 55 0 C.
- Universal bases are described in "Survey and Summary: The Applications of Universal DNA base analogues" Loakes, D., Nucleic Acid Research 2001, 29, 2437, which is incorporated by reference in its entirety. Specific examples are described in the following: Liu, D.; Moran, S.; Kool, E. T. Chem. Biol., 1997, 4, 919-926; Morales, J. C; Kool, E. T. Biochemistry, 2000, 39, 2626-2632; Matray, T, J.; Kool, E. T. J. Am. Chem. Soc, 1998, 120, 6191-6192; Moran, S. Ren, R. X.-F.; Rumney IV, S.; Kool, E. T. J.
- modified RNA molecules or polymeric molecules comprising any combination of monomer compounds described herein and/or natural or modified ribonucleotides in which one or more subunits contain an unusual or universal base.
- Modified RNA molecules include e.g.
- nucleoside surrogate those molecules containing a chemically or stereochemically modified nucleoside ⁇ e.g., having one or more backbone modifications, e.g., phosphorothioate or P-alkyl; having one or more sugar modifications, e.g., 2'-OCH 3 or 2'-F; and/or having one or more base modifications, e.g., 5-alkylamino or 5-allylamino) or a nucleoside surrogate.
- backbone modifications e.g., phosphorothioate or P-alkyl
- sugar modifications e.g., 2'-OCH 3 or 2'-F
- base modifications e.g., 5-alkylamino or 5-allylamino
- phosphite ester intermediates which in turn are oxidized e.g., with iodine, to the phosphate diester.
- the phosphites may be treated with, e.g., sulfur, selenium, amino, and boron reagents to form modified phosphate backbones.
- Linkages between the monomers described herein and a nucleoside or oligonucleotide chain can also be treated with iodine, sulfur, selenium, amino, and boron reagents to form unmodified and modified phosphate backbones respectively.
- the monomers described herein may be coupled with nucleosides or oligonucleotides containing any of the modifications or nucleoside surrogates described herein.
- oligonucleotide peptide conjugates can be performed by established methods. See, for example, Trufert et ah, Tetrahedron, 52:3005, 1996; and Manoharan, "Oligonucleotide Conjugates in Antisense Technology," in Antisense Drug Technology, ed. S.T. Crooke, Marcel Dekker, Inc., 2001. Exemplary methods are shown in FIGs. 4 and 5.
- a peptidomimetic can be modified to create a constrained peptide that adopts a distinct and specific preferred conformation, which can increase the potency and selectivity of the peptide.
- the constrained peptide can be an azapeptide (Gante, Synthesis, 1989, 405-413).
- An azapeptide is synthesized by replacing the ⁇ -carbon of an amino acid with a nitrogen atom without changing the structure of the amino acid side chain.
- the azapeptide can be synthesized by using hydrazine in traditional peptide synthesis coupling methods, such as by reacting hydrazine with a "carbonyl donor," e.g., phenylchloroformate.
- a general azapeptide synthesis is shown in FIG. 6.
- a peptide or peptidomimetic ⁇ e.g., a peptide or peptidomimetic tethered to an ligand-conjugated monomer can be an N-methyl peptide.
- N- methyl peptides are composed of N-methyl amino acids, which provide an additional methyl group in the peptide backbone, thereby potentially providing additional means of resistance to proteolytic cleavage.
- N-methyl peptides can by synthesized by methods known in the art (see, for example, Lindgren et al, Trends Pharmacol. Sci. 21:99, 2000; Cell Penetrating Peptides: Processes and Applications, Langel, ed., CRC Press, Boca Raton, FL, 2002; Fische et ah,
- an Ant or Tat peptide can be an N-methyl peptide.
- An exemplary synthesis is shown in FIG. 7.
- a peptide or peptidomimetic e.g., a peptide or peptidomimetic tethered to a ligand-conjugated monomer
- a oligopeptide or peptidomimetic can be a /3-peptide.
- /3-peptides form stable secondary structures such as helices, pleated sheets, turns and hairpins in solutions. Their cyclic derivatives can fold into nanotubes in the solid state.
- /3-peptides are resistant to degradation by proteolytic enzymes.
- /3-peptides can be synthesized by methods known in the art.
- an Ant or Tat peptide can be a /3-peptide.
- An exemplary synthesis is shown in FIG. 8.
- a peptide or peptidomimetic e.g., a peptide or peptidomimetic tethered to a ligand-conjugated monomer
- a oligocarbamate e.g., a peptide or peptidomimetic tethered to a ligand-conjugated monomer
- Oligocarbamate peptides are internalized into a cell by a transport pathway facilitated by carbamate transporters.
- an Ant or Tat peptide can be an oligocarbamate.
- An exemplary synthesis is shown in FIG. 9.
- a peptide or peptidomimetic e.g., a peptide or peptidomimetic tethered to a ligand-conjugated monomer
- a peptide or peptidomimetic can be an oligourea conjugate (or an oligothiourea conjugate), in which the amide bond of a peptidomimetic is replaced with a urea moiety. Replacement of the amide bond provides increased resistance to degradation by proteolytic enzymes, e.g., proteolytic enzymes in the gastrointestinal tract.
- an oligourea conjugate is tethered to an oligonucleotide agent for use in oral delivery.
- the backbone in each repeating unit of an oligourea peptidomimetic can be extended by one carbon atom in comparison with the natural amino acid.
- the single carbon atom extension can increase peptide stability and lipophilicity, for example.
- An oligourea peptide can therefore be advantageous when an oligonucleotide agent is directed for passage through a bacterial cell wall, or when an oligonucleotide agent must traverse the blood-brain barrier, such as for the treatment of a neurological disorder.
- a hydrogen bonding unit is conjugated to the oligourea peptide, such as to create an increased affinity with a receptor.
- an Ant or Tat peptide can be an oligourea conjugate (or an oligothiourea conjugate).
- An exemplary synthesis is shown in FIG. 10.
- the siRNA peptide conjugates of the invention can be affiliated with, e.g., tethered to, ligand-conjugated monomers occurring at various positions on an oligonucleotide agent.
- a peptide can be terminally conjugated, on either the sense or the antisense strand, or a peptide can be bisconjugated (one peptide tethered to each end, one conjugated to the sense strand, and one conjugated to the antisense strand).
- the peptide can be internally conjugated, such as in the loop of a short hairpin oligonucleotide agent.
- the peptide can be affiliated with a complex, such as a peptide-carrier complex.
- a peptide-carrier complex consists of at least a carrier molecule, which can encapsulate one or more oligonucleotide agents (such as for delivery to a biological system and/or a cell), and a peptide moiety tethered to the outside of the carrier molecule, such as for targeting the carrier complex to a particular tissue or cell type.
- a carrier complex can carry additional targeting molecules on the exterior of the complex, or fusogenic agents to aid in cell delivery.
- the one or more oligonucleotide agents encapsulated within the carrier can be conjugated to lipophilic molecules, which can aid in the delivery of the agents to the interior of the carrier.
- a carrier molecule or structure can be, for example, a micelle, a liposome ⁇ e.g., a cationic liposome), a nanoparticle, a microsphere, or a biodegradable polymer.
- a peptide moiety can be tethered to the carrier molecule by a variety of linkages, such as a disulfide linkage, an acid labile linkage, a peptide-based linkage, an oxyamino linkage or a hydrazine linkage.
- a peptide-based linkage can be a GFLG peptide.
- the protected monomer compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
- a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
- the protected monomer compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
- the compounds described herein can also contain linkages (e.g., carbon-carbon bonds, carbon-nitrogen bonds, e.g., amides) or substituents that can restrict bond rotation , e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans, E/Z isomers, and rotational isomers (rotamers) are expressly included herein.
- the compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein (e.g., alkylation of a ring system may result in alkylation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
- protecting groups for ligand-conjugated monomer hydroxyl groups include but are not limited to the dimethoxytrityl group (DMT).
- DMT dimethoxytrityl group
- 25 & 26 can be used for 3 ⁇ 5'- conjugation respectively.
- conjugation of a ligand to an oligonucleotide agent e.g., an oligonucleotide agent that targets an miRNA or pre-miRNA can have a favorable effect on the modulating effect of the agent.
- the agent can improve pharmacokinetics, stability, and/or tissue specificity.
- an oligonucleotide agent (referred to as "NA" in formula OT-I through OT-rV below, e.g., RNA, DNA, chimeric RNA-DNA, DNA-RNA, RNA-DNA-RNA, or DNA-RNA-DNA) can be chemically modified by conjugating a moiety that includes a ligand having one or more chemical linkages for attachment of the ligand (L) to the oligonucleotide or nucleic acid.
- the ligand of an oligonucleotide agent can be coupled by one or both of a tether and linker.
- exemplary chemical linkages are represented as X, Y, and Z. These can be part of the tether or linker. -X-C Tether Y- Y— Linker -Z— NA ] (OT-I)
- Ligands can be attached at one or both of the 3' end, the 5' end, and internal positions.
- the oligonucleotide agent can be chemically modified by conjugating one or more moieties having formula OT-I. Table 3, shows a variety of conjugates.
- Ligand I Tether Linker 5'- NA L 3 .
- Exemplary ligands are listed in Table 4 and are discussed elsewhere herein.
- the exemplary ligands (L) shown in Table 4 are preferred. Table 4.
- Amines (mono, di, tri, tetraalkyl or aryl)
- Dialkylglycerol (sn3, sn1 , sn2 and racemic) with number of methylene varies from 0-40
- Dlacylglycerol (sn3, sn1 , sn2 and racemic) with number of methylene varies from 0-40
- Dialkylglycerol (sn3, sn1 , sn2 and racemic) with number of methylene varies from 0-40 and the alkyl chian contains one or more double bonds with E and/or Z isomers
- Dlacylglycerol (sn3, sn1 , sn2 and racemic) with number of methylene varies from 0-40 and the alkyl chian contains one or more double bonds with E and/or Z isomers Lipids
- Exemplary X, Y 3 and Z moieties are shown in in Table 5.
- the X, Y, and Z moieties can selected independently of one another. Table 5.
- R Alkyl, fluroalkyl, aryl or aralkyl
- Exemplary tethers are shown in Table 7.
- Compound 1 is prepared as reported by Fraser (Tetrahedron Lett. 41:1523, 2000). Steps (ii), (iii) (a), (iii) (c), (iv), (v) and (vii) are performed according to literature procedure (Fraser et ah, Tetrahedron Lett. 41:1523, 2000). Step (iii) (b) and (v) (b) are performed as reported in the literature (Bioorg. Med. Chem. Lett. 13:1713, 2003). Step (iv) is performed as reported in the literature (Corey and Venkateswarlu, J. Am. Chem. Soc. 94:6190, 1972).
- Step (i) is performed as reported in Dubowchik and Radia (Tetrahedron Lett., 38:5257, 1997); step (ii) is performed as reported in Corey and Venkateswarlu (J. Am. Chem. Soc. 94:6190, 1972); step (iii) is performed as reported in Fraser et al. (Tetrahedron Lett. 41:1523, 2000) and step (iv) is performed as described in Miller et al. (Current Protocol in Nucleic Acids Chemistry, 2000, 2.5.1-2.5.36, John Wiley and Sons, Inc.).
- step (i) is performed as described in Miller et al. (Current Protocol in Nucleic Acids Chemistry, 2000, 2.5.1-2.5.36, John Wiley and Sons, Inc.); step (ii) is performed as reported in the Corey and Venkateswarlu (J. Am. Chem. Soc. 94:6190, 1972) and step (iii) is performed as reported by Fraser et al. (Tetrahedron Lett. 41:1523, 2000).
- Pentaflurophenyl benzoate/Py (ii) TBDMS-Cl, Imidazole/Py; (iii) diisopropylamine tetrazolide, 2-cyanoethyl- ⁇ r ,N,N', ⁇ '"-tetraisopropylphospliorainidite/CH2Cl2
- step (iv) (a) is performed as reported in the literature (Organic Lett., 2001, 3, 1809); step (v) is performed as reported in Corey and Venkateswarlu (J. Am. Chem. Soc. 94:6190, 1972) and step (vi) is performed as reported by Fraser et al. (Tetrahedron Lett. 41:1523, 2000).
- step (iii) (d) is performed as reported in Dubowchik and Radia (Tetrahedron Lett., 1997, 38, 5257);
- step (iv) (a) is performed as reported in the literature (Organic Lett., 2001, 3, 1809);
- step (v) is performed as reported in Corey and Venkateswarlu (J. Am. Chem. Soc, 1972, 94, 6190) and
- step (vi) is performed as reported by Fraser et al. (Tetrahedron Lett., 2000, 41, 1523)
- oligonucleotide agents featured in the invention can be targeted to particular tissues or cell types.
- an oligonucleotide agent can be targeted to the liver, kidney, a cell of the nervous system, or a muscle cell.
- an oligonucleotide agent can includean SRMS containing a ligand that targets the liver, e.g., a lipophilic moiety. Lipophilic moieties include lipid, cholesterols, oleyl, retinyl, or cholesteryl residues.
- liver-targeting agents include cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.
- An oligonucleotide agent can also be targeted to the liver by association with a low-density lipoprotein (LDL), such as lactosylated LDL.
- LDL low-density lipoprotein
- Polymeric carriers complexed with sugar residues can also function to target oligonucleotide agents to the liver.
- Conjugation of an oligonucleotide agent with a serum albumin (SA), such as human serum albumin, can also be used to target the oligonucleotide agent to a non-kidney tissue.
- SA serum albumin
- an oligonucleotide agent targeted to a tissue by an SRMS targeting moiety described herein can target a gene expressed in the tissue.
- an oligonucleotide agent targeted to the liver can target p21 (WAFl /DIPl), P27(KIP1), beta-catenin, or c-MET, such as for treating a cancer of the liver.
- the oligonucleotide agent can target apoB- 100, such as for the treatment of an HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined hyperlipidemia (FCHL), or acquired hyperlipidemia; hypercholesterolemia; statin-resistant hypercholesterolemia; coronary artery disease (CAD); coronary heart disease (CHD); or atherosclerosis.
- dyslipidemias e.g., familial combined hyperlipidemia (FCHL), or acquired hyperlipidemia
- hypercholesterolemia e.g., familial combined hyperlipidemia (FCHL), or acquired hyperlipidemia
- hypercholesterolemia CAD
- statin-resistant hypercholesterolemia CAD
- coronary heart disease (CHD) coronary heart disease
- atherosclerosis e.g., atherosclerosis.
- a targeting agent that incorporates a sugar, e.g., galactose and/or analogues thereof, can be useful. These agents target, for example, the parenchymal cells of the liver.
- a targeting moiety can include more than one or preferably two or three galactose moieties, spaced about 15 angstroms from each other.
- the targeting moiety can alternatively be lactose ⁇ e.g., three lactose moieties), which is glucose coupled to a galactose.
- the targeting moiety can also be N-Acetyl-Galactosamine, N-Ac-Glucosamine.
- Amannose or mannose-6-phosphate targeting moiety can be used for macrophage targeting.
- oligonucleotide agents of the invention can also be targeted to the kidney, e.g., by incorporation of an SRMS containing a ligand that targets the kidney.
- An oligonucleotide agent targeted to the kidney by an SRMS targeting moiety described herein can target a gene expressed in the kidney.
- Ligands on SRMSs can include folic acid, glucose, cholesterol, cholic acid, Vitamin E,
- Vitamin K or Vitamin A.
- Oligonucleotide agents such as an miRNA olionucleotide agents targeting miRNAs or pre-miRNAs, can be modified so as to enhance entry into cells, e.g., an endocytic or non- endocytic mechanism.
- a ligand that increases cell permeability can be attached to an oligonucleotide agent in a number of ways, such as by attachment to an SRMS, e.g., pyrroline- based SRMS.
- an oligonucleotide can be conjugated to a polyarginine that will enhance uptake into a wide range of cell-types. While not being bound by theory, the enhanced uptake is believed to be by a nonendocytic route.
- an oligonucleotide can be conjugated to a guanidium analog of an aminoglycoside to promote cell permeability.
- an oligonucleotide in another embodiment, can be conjugated with a lipophilic moiety.
- the lipophilic moiety can be attached at the nitrogen atom of a pyrroline-based SRMS.
- lipophilic moieties include cholesterols, lipid, oleyl, retinyl, or cholesteryl residues.
- lipophilic moieties include cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3- (oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.
- Cholesterol is a particularly preferred example.
- the ligand that enhances cell permeability can be attached at the 3' terminus, the 5 'terminus, or internally.
- the ligand can be attached to an SRMS, e.g., a pyrroline-based SRMS at the 3' terminus, the 5 'terminus, or at an internal linkage.
- the attachment can be direct or through a tethering molecule. Tethers, spacers or linkers discussed herein can be used to attach the moiety to the SRMS.
- An oligonucleotide agent to which one or more cell-permeability ligands is conjugated can be delivered in vivo, e.g., to a cell, such as a cell of a tissue in a subject, such as a mammalian subject (e.g., a human or mouse).
- the oligonucleotide agent can be delivered in vitro, e.g., to a cell in a cell line.
- Cell lines can be, for example, from a vertebrate organism, such as a mammal (e.g., a human or a mouse).
- Delivery of an OA-cell permeability conjugate to a cell line can be in the absence of other transfection reagents.
- delivery of an OA-cell permeability conjugate to a cell can be in the absence of, or optionally, in the presence of, Lipofectamine (Invitrogen, Carlsbad, CA), Lipofectamine 2000TM, TransIT-TKOTM (Minis, Madison, WI), FuGENE 6 (Roche, Indianapolis, IN), polyethylenimine, X-tremeGENE Q2 (Roche,
- OA-cell permeability conjugate can be delivered to a cell line, such as any cell line described herein, to target a specific gene for downregulation.
- an oligonucleotide agent-lipophilic conjugate can be delivered to a primary cell line, e.g., a synoviocyte (such as type B), cardiac myocyte, keratinocyte, hepatocyte, smooth muscle cell, endothelial cell, or dermal fibroblast cell line.
- a synoviocyte such as type B
- cardiac myocyte keratinocyte
- hepatocyte smooth muscle cell
- endothelial cell or dermal fibroblast cell line.
- An oligonucleotide agent that is NAT (“nucleic acid targeting”) includes a region of sufficient complementarity to the target gene, and is of sufficient length in terms of nucleotides, such that the oligonucleotide agent forms a duplex with the target nucleic acid.
- the oligonucleotide agent can modulate the function of the targeted molecule.
- the NAT when the targeted molecule is an mRNA or pre-mRNA, the NAT can inhibit gene expression; when the target is an miRNA, the NAT will inhibit the miRNA function and will thus up-regulate expression of the mRNAs targeted by the particular miRNA; when the target is a region of a pre- mRNA the affects splicing, the NAT can alter the choice of splice site and thus the mRNA sequence; when the NAT functions as an miRNA, expression of the targeted mRNA is inhibited.
- nucleotide or ribonucleotide is sometimes used herein in reference to one or more monomeric subunits of an oligonucleotide agent.
- ribonucleotide or “nucleotide” herein can, in the case of a modified RNA or nucleotide surrogate, also refer to a modified nucleotide, or surrogate replacement moiety at one or more positions.
- ANAT oligonucleotide agent is, or includes, a region that is at least partially, and in some embodiments fully, complementary to the target RNA. It is not necessary that there be perfect complementarity between the oligonucleotide agent and the target, but the correspondence must be sufficient to enable the oligonucleotide agent, or a cleavage product thereof, to modulate (e.g., inhibit) target gene expression.
- An oligonucleotide agent will preferably have one or more of the following properties:
- RNA-like properties i.e., it will possess the overall structural, chemical and physical properties of an RNA molecule, even though not exclusively, or even partly, of ribonucleotide-based content.
- all of the nucleotide sugars can contain e.g., 2'OMe, 2' fluoro in place of 2' hydroxyl.
- This deoxyribonucleotide-containing agent can still be expected to exhibit RNA-like properties.
- the electronegative fluorine prefers an axial orientation when attached to the C2' position of ribose.
- fluorine is a good hydrogen bond acceptor, it can participate in the same hydrogen bonding interactions with water molecules that are known to stabilize RNA structures. (Generally, it is preferred that a modified moiety at the 2' sugar position will be able to enter into hydrogen-bonding which is more characteristic of the 2'-OH moiety of a ribonucleotide than the 2'-H moiety of a deoxyribonucleotide.
- a preferred oligonucleotide agent will: exhibit a Cy-endo pucker in all, or at least 50, 75,80, 85, 90, or 95 % of its sugars; exhibit a Cy-endo pucker in a sufficient amount of its sugars that it can give rise to a the RNA-characteristic A-family-type helix; will have no more than 20, 10, 5, 4, 3, 2, orl sugar which is not a Cy-endo pucker structure.
- Preferred 2 '-modifications with C3'-endo sugar pucker include:
- oligonucleotide agent can contain deoxynucleotides or modified deoxynucleotides, it is preferred that DNA molecules, or any molecule in which more than 50, 60, or 70 % of the nucleotides in the molecule are deoxyribonucleotides, or modified deoxyribonucleotides which are deoxy at the 2' position, are excluded from the definition of oligonucleotide agent.
- Preferred 2 '-modifications with a C2'-endo sugar pucker include:
- Sugar modifications can also include L-sugars and 2'-5'-linked sugars.
- telomere binding requires a sufficient lack of complementarity to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vitro assays, under conditions in which the assays are performed. It has been shown that a single mismatch between targeted and non-targeted sequences are sufficient to provide discrimination for siRNA targeting of an mRNA (Brummelkamp et ah, Cancer Cell, 2002, 2:243).
- a NAT oligonucleotide agent is "sufficiently complementary" to a target RNA, such that the oligonucleotide agent inhibits production of protein encoded by the target mRNA.
- the target RNA can be, e.g. , a pre-mRNA, mRNA, or miRNA endogenous to the subject,
- the oligonucleotide agent is "exactly complementary" (excluding the SRMS containing subunit(s)) to a target RNA, e.g., the target RNA and the oligonucleotide agent can anneal to form a hybrid made exclusively of Watson-Crick base pairs in the region of exact complementarity.
- a "sufficiently complementary" target RNA can include a region (e.g., of at least 7 nucleotides) that is exactly complementary to a target RNA.
- the oligonucleotide agent specifically discriminates a single- nucleotide difference.
- the oligonucleotide agent only down-regulates gene expression if exact complementarity is found in the region the single-nucleotide difference.
- Oligonucleotide agents discussed herein include otherwise unmodified RNA and DNA as well as RNA and DNA that have been modified, e.g., to improve efficacy, and polymers of nucleoside surrogates.
- Unmodified RNA refers to a molecule in which the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are the same or essentially the same as that which occur in nature, preferably as occur naturally in the human body.
- the art has referred to rare or unusual, but naturally occurring, RNAs as modified RNAs, see, e.g., Limbach et al. ⁇ Nucleic Acids Res., 1994, 22:2183-2196).
- modified RNA refers to a molecule in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occur in nature, preferably different from that which occurs in the human body. While they are referred to as "modified RNAs" they will of course, because of the modification, include molecules that are not, strictly speaking, RNAs.
- Nucleoside surrogates are molecules in which the ribophosphate backbone is replaced with a non- ribophosphate construct that allows the bases to the presented in the correct spatial relationship such that hybridization is substantially similar to what is seen with a ribophosphate backbone, e.g., non-charged mimics of the ribophosphate backbone. Examples of all of the above are discussed herein.
- nucleic acids are polymers of subunits or monomers
- many of the modifications described below occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety.
- the modification will occur at all of the subject positions in the nucleic acid but in many, and infact in most cases it will not.
- a modification may only occur at a 3' or 5' terminal position, may only occur in a terminal regions, e.g. at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand.
- the ligand can be at attached at the 3' end, the 5' end, or at an internal position, or at a combination of these positions.
- the ligand can be at the 3' end and the 5' end; at the 3' end and at one or more internal positions; at the 5' end and at one or more internal positions; or at the 3' end, the 5' end, and at one or more internal positions.
- a phosphorothioate modification at a non-linking O position may only occur at one or both termini, or may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of the oligonucleotide.
- the 5' end can be phosphorylated.
- the scaffold presented above in Formula 1 represents a portion of a ribonucleic acid.
- the basic components are the ribose sugar, the base, the terminal phosphates, and phosphate internucleotide linkers.
- the bases are naturally occurring bases, e.g., adenine, uracil, guanine or cytosine
- the sugars are the unmodified 2' hydroxyl ribose sugar (as depicted) and W, X, Y, and Z are all O
- Formula 1 represents a naturally occurring unmodified oligoribonucleotide.
- Unmodified oligoribonucleotides may be less than optimal in some applications, e.g., unmodified oligoribonucleotides can be prone to degradation by e.g., cellular nucleases. Nucleases can hydrolyze nucleic acid phosphodiester bonds. However, chemical modifications to one or more of the above RNA components can confer improved properties, and, e.g., can render oligoribonucleotides more stable to nucleases. Unmodified oligoribonucleotides may also be less than optimal in terms of offering tethering points for attaching ligands or other moieties to an oligonucleotide agent. Modified nucleic acids and nucleotide surrogates can include one or more of:
- the W position at the 5' end of a nucleic acid and the terminal Z position at the 3' end of a nucleic acid are within the term "linking phosphate oxygens" as used herein.); (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2' hydroxyl on the ribose sugar, or wholesale replacement of the ribose sugar with a structure other than ribose, e.g., as described herein;
- modification of the 3' end or 5' end of the RNA e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, e.g. a fluorescently labeled moiety, to either the 3' or 5' end of RNA.
- the actual electronic structure of some chemical entities cannot be adequately represented by only one canonical form ⁇ i.e. Lewis structure). While not wishing to be bound by theory, the actual structure can instead be some hybrid or weighted average of two or more canonical forms, known collectively as resonance forms or structures.
- Resonance structures are not discrete chemical entities and exist only on paper. They differ from one another only in the placement or "localization" of the bonding and nonbonding electrons for a particular chemical entity. It can be possible for one resonance structure to contribute to a greater extent to the hybrid than the others.
- the phosphate group is a negatively charged species.
- the charge is distributed equally over the two non-linking oxygen atoms (i.e., X and Y in Formula 1 above).
- the phosphate group can be modified by replacing one of the oxygens with a different substituent.
- One result of this modification to RNA phosphate backbones can be increased resistance of the oligoribonucleotide to nucleolytic breakdown.
- modified phosphate groups include phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters.
- Phosphorodithioates have both non-linking oxygens replaced by sulfur. Unlike the situation where only one of X or Y is altered, the phosphorus center in the phosphorodithioates is achiral which precludes the formation of oligoribonucleotides diastereomers. Diastereomer formation can result in a preparation in which the individual diastereomers exhibit varying resistance to nucleases.
- RNA containing chiral phosphate groups can be lower relative to the corresponding unmodified RNA species.
- modifications to both X and Y which eliminate the chiral center, e.g. phosphorodithioate formation may be desirable in that they cannot produce diastereomer mixtures.
- X can be any one of S, Se, B, C, H, N, or OR (R is alkyl or aryl).
- Y can be any one of S, Se, B, C, H, N, or OR (R is alkyl or aryl). Replacement of X and/or Y with sulfur is preferred.
- the phosphate linker can also be modified by replacement of a linking oxygen (i.e., W or Z in Formula 1) with nitrogen (bridged phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates).
- the replacement can occur at a terminal oxygen (position W (3') or position Z (5'). Replacement of W with carbon or Z with nitrogen is preferred.
- a linking oxygen i.e., W or Z in Formula 1
- nitrogen bridged phosphoroamidates
- sulfur bridged phosphorothioates
- carbon bridged methylenephosphonates
- a modified RNA can include modification of all or some of the sugar groups of the ribonucleic acid.
- the 2' hydroxyl group (OH) can be modified or replaced with a number of different "oxy" or "deoxy” substituents. While not being bound by theory, enhanced stability is expected since the hydroxyl can no longer be deprotonated to form a 2' alkoxide ion.
- the 2' alkoxide can catalyze degradation by intramolecular nucleophilic attack on the linker phosphorus atom.
- MOE methoxyethyl group
- Preferred substitutents are T- methoxyethyl, 2'-OCH3, 2'-0-allyl, 2'-C- allyl, and 2'-fmoro.
- the sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose.
- a modified RNA can include nucleotides containing e.g., arabinose, as the sugar.
- Modified RNAs can also include "abasic" sugars, which lack a nucleobase at C-I'. These abasic sugars can also be further contain modifications at one or more of the constituent sugar atoms.
- the 2' modifications can be used in combination with one or more phosphate linker modifications (e.g., phosphorothioate).
- phosphate linker modifications e.g., phosphorothioate
- the so-called "chimeric" oligonucleotides are those that contain two or more different modifications.
- the modification can also entail the wholesale replacement of a ribose structure with another entity at one or more sites in the oligonucleotide agent.
- the phosphate group can be replaced by non-phosphorus containing connectors (cf. Bracket I in Formula 1 above). While not wishing to be bound by theory, it is believed that since the charged phosphodiester group is the reaction center in nucleolytic degradation, its replacement with neutral structural mimics should impart enhanced nuclease stability. Again, while not wishing to be bound by theory, it can be desirable, in some embodiment, to introduce alterations in which the charged phosphate group is replaced by a neutral moiety.
- moieties which can replace the phosphate group include siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.
- Preferred replacements include the methylenecarbonylamino and methylenemethylimino groups.
- Oligonucleotide- mimicking scaffolds can also be constructed wherein the phosphate linker and ribose sugar are replaced by nuclease resistant nucleoside or nucleotide surrogates (see Bracket II of Formula 1 above). While not wishing to be bound by theory, it is believed that the absence of a repetitively charged backbone diminishes binding to proteins that recognize polyanions (e.g. nucleases). Again, while not wishing to be bound by theory, it can be desirable in some embodiment, to introduce alterations in which the bases are tethered by a neutral surrogate backbone.
- Examples include the mophilino, cyclobutyl, pyrrolidine and peptide nucleic acid (PNA) nucleoside surrogates.
- a preferred surrogate is a PNA surrogate.
- the 3' and 5' ends of an oligonucleotide can be modified. Such modifications can be at the 3' end, 5' end or both ends of the molecule. They can include modification or replacement of an entire terminal phosphate or of one or more of the atoms of the phosphate group.
- the 3' and 5' ends of an oligonucleotide can be conjugated to other functional molecular entities such as labeling moieties, e.g., fluorophores (e.g., pyrene, TAMRA, fluorescein, Cy3 or Cy5 dyes) or protecting groups (based e.g., on sulfur, silicon, boron or ester).
- labeling moieties e.g., fluorophores (e.g., pyrene, TAMRA, fluorescein, Cy3 or Cy5 dyes) or protecting groups (based e.g., on sulfur, silicon, boron or ester).
- the functional molecular entities can be attached to the sugar through a phosphate group and/or a spacer.
- the terminal atom of the spacer can connect to or replace the linking atom of the phosphate group or the C-3' or C-5' O, N, S or C group of the sugar.
- the spacer can connect to or replace the terminal atom of a nucleotide surrogate (e.g., PNAs).
- terminal modifications include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g.
- EDTA lipophilic carriers
- lipophilic carriers e.g., cholesterol, cholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, 03- (oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG] 2 , polyamin
- biotin e.g., aspirin, vitamin E, folic acid
- transport/absorption facilitators e.g., aspirin, vitamin E, folic acid
- synthetic ribonucleases e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles.
- Terminal modifications can be added for a number of reasons, including as discussed elsewhere herein to modulate activity or to modulate resistance to degradation.
- Preferred modifications include the addition of a methylphosphonate at the 3 '-most terminal linkage; a 3' C5-aminoalkyl-dT; 3' cationic group; or another 3' conjugate to inhibit 3 '-5' exonucleolytic degradation.
- Terminal modifications useful for modulating activity include modification of the 5' end with phosphate or phosphate analogs.
- oligonucleotide agents are 5' phosphorylated or include a phosphoryl analog at the 5' terminus.
- 5'-phosphate modifications include those which are compatible with RISC mediated gene silencing. Suitable modifications include: 5 '-monophosphate ((HO)2(O)P-O-5'); 5'-diphosphate ((HO)2(O)P-O-P(HO)(O)-O-5'); 5'-tri ⁇ hosphate ((HO)2(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5 !
- 5'-guanosine cap (7-methylated or non-methylated) (7m-G-O-5'-(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N-O-5 '-(HO)(O)P-O- (HO)(O)P-O-P(HO)(O)-O-5'); 5'-monothiophosphate (phosphorothioate; (HO)2(S)P-O-5'); 5'- monodithiophosphate (phosphorodithioate; (HO)(HS)(S)P-O-5'), 5'-phosphorothiolate ((HO)2(O)P-S-5'); any additional combination of oxgen/sulfur replaced monophosphate, diphosphate and triphosphates (e.g.
- Terminal modifications can also be useful for monitoring distribution, and in such cases the preferred groups to be added include fluorophores, e.g., fluorscein or an Alexa dye, e.g., Alexa 488. Terminal modifications can also be useful for enhancing uptake, useful modifications for this include cholesterol. Terminal modifications can also be useful for cross- linking anoligonucleotide agent to another moiety; modifications useful for this include mitomycin C. Candidate modifications can be evaluated as described below.
- Adenine, guanine, cytosine and uracil are the most common bases found in RNA. These bases can be modified or replaced to provide RNA' s having improved properties.
- nuclease resistant oligoribonucleotides can be prepared with these bases or with synthetic and natural nucleobases (e.g., inosine, thymine, xanthine, hypoxanthine, nubularine, isoguanisine, or tubercidine) and any one of the above modifications.
- substituted or modified analogs of any of the above bases e.g., "unusual bases” and "universal bases” described herein, can be employed.
- Examples include without limitation 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropyl)uracil, 5-amino allyl uracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 5- substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2- amino
- base changes are less preferred for promoting stability, but they can be useful for other reasons, e.g., some, e.g., 2,6-diaminopurme and 2 amino purine (e.g., 2-amino adenine), are fluorescent. Modified bases can reduce target specificity. This should be taken into consideration in the design of oligonucleotide agents.
- a candidate oligonucleotide agent e.g., a modified oligonucleotide agent
- a selected property by exposing the agent or modified molecule and a control molecule to the appropriate conditions and evaluating for the presence of the selected property.
- resistance to a degradent can be evaluated as follows.
- a candidate modified RNA (and preferably a control molecule, usually the unmodified form) can be exposed to degradative conditions, e.g., exposed to a milieu, which includes a degradative agent, e.g., a nuclease.
- a biological sample e.g., one that is similar to a milieu, which might be encountered, in therapeutic use, e.g., blood or a cellular fraction, e.g., a cell-free homogenate or disrupted cells.
- the candidate and control could then be evaluated for resistance to degradation by any of a number of approaches.
- the candidate and control could be labeled, preferably prior to exposure, with, e.g., a radioactive or enzymatic label, or a fluorescent label, such as Cy3 or Cy5.
- Control and modified RNA's can be incubated with the degradative agent, and optionally a control, e.g., an inactivated, e.g., heat inactivated, degradative agent.
- a physical parameter, e.g., size, of the modified and control molecules are then determined. They can be determined by a physical method, e.g., by polyacrylamide gel electrophoresis or a sizing column, to assess whether the molecule has maintained its original length, or assessed functionally. Alternatively, Northern blot analysis can be used to assay the length of an unlabeled modified molecule.
- a functional assay can also be used to evaluate the candidate agent.
- a functional assay can be applied initially or after an earlier non-functional assay, (e.g., assay for resistance to degradation) to determine if the modification alters the ability of the molecule to inhibit gene expression.
- a cell e.g., a mammalian cell, such as a mouse or human cell
- a plasmid expressing a fluorescent protein, e.g., GFP, and a candidate oligonucleotide agent homologous to the transcript encoding the fluorescent protein (see, e.g., WO 00/44914).
- a modified oligonucleotide agent homologous to the GFP mRNA can be assayed for the ability to inhibit GFP expression by monitoring for a decrease in cell fluorescence, as compared to a control cell, in which the transfection did not include the candidate oligonucleotide agent, e.g., controls with no agent added and/or controls with a non- modified RNA added.
- Efficacy of the candidate agent on gene expression can be assessed by comparing cell fluorescence in the presence of the modified and unmodified oligonucleotide agent.
- a candidate oligonucleotide agent homologous to an endogenous mouse gene preferably a maternally expressed gene, such as c-mos
- a phenotype of the oocyte e.g., the ability to maintain arrest in metaphase II, can be monitored as an indicator that the agent is inhibiting expression. For example, cleavage of c-mos mRNA by an oligonucleotide agent would cause the oocyte to exit metaphase arrest and initiate parthenogenetic development (Colledge et al.
- Controls can include cells in which with no agent is added and/or cells in which a non- modified RNA is added.
- an oligonucleotide agent that targets an miRNA ore pre-miRNA can be assayed by monitoring expression of the transcript targeted by the miRNA.
- an oligonucleotide agent designed to bind an miRNA that targets GFP can be assessed by monitoring for an increase in cell fluorescence, as compared to a control cell, in which the transfection did not include the candidate oligonucleotide agent, e.g., controls with no agent added and/or controls with a non- modified RNA added.
- an oligonucleotide agent designed to bind an miRNA that targets an endogenous enzyme can be assessed by monitoring for an increase in enzyme activity, as compared to a control cell. The effect of the modified oligonucleotide agent on target miRNA levels can be verified by Northern blot to assay for a decrease in the level of the target miRNA.
- oligoribonucleotides and oligoribonucleosides used in accordance with this invention may be with solid phase synthesis, see for example "Oligonucleotide synthesis, a practical approach", Ed. M. J. Gait, IRL Press, 1984; “Oligonucleotides and Analogues, A Practical Approach”, Ed. F.
- phosphinate oligoribonucleotides The preparation of phosphinate oligoribonucleotides is described in U.S. Pat. No. 5,508,270. The preparation of alkyl phosphonate oligoribonucleotides is described in U.S. Pat. No. 4,469,863. The preparation of phosphoramidite oligoribonucleotides is described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878. The preparation of phosphotriester oligoribonucleotides is described in U.S. Pat. No. 5,023,243. The preparation of borano phosphate oligoribonucleotide is described in U.S. Pat. Nos. 5,130,302 and 5,177,198.
- MMI linked oligoribonucleosides also identified herein as MMI linked oligoribonucleosides, methylenedimethylhydrazo linked oligoribonucleosides, also identified herein as MDH linked oligoribonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified herein as amide-3 linked oligoribonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified herein as amide-4 linked 5 oligoribonucleosides as well as mixed backbone compounds having, as for instance, alternating MMI and PO or PS linkages can be prepared as is described in U.S.
- Carbonate replacements are described in Tittensor, J.R. J. Chem. Soc. C 1971, 1933. Carboxymethyl replacements are described in Edge, M.D. et al. J. Chem. Soc. Perkin Trans. 1 1972, 1991. Carbamate replacements are described in Stirchak, E.P. 5 Nucleic Acids Res. 1989, 17, 6129.
- Cyclobutyl sugar surrogate compounds can be prepared as is described in U.S. Pat. No. 5,359,044. Pyrrolidine sugar surrogate can be prepared as is described in U.S. Pat. No. 0 5,519,134. Morpholino sugar surrogates can be prepared as is described in U.S. Pat. Nos.
- PNAs Peptide Nucleic Acids
- PNA Peptide Nucleic Acids
- N-2 substitued purine nucleoside amidites can be prepared as is described in U.S. Pat.
- 5,6-Substituted pyrimidine nucleoside amidites can be prepared as is described in
- Preferred oligonucleotide agents have the following structure (see Formula 2 below):
- R 1 , R 2 , and R 3 are each, independently, H, (i.e. abasic nucleotides), adenine, guanine, cytosine and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidine, isoguanisine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 5-halouracil, 5-(2-aminopropyl)uracil, 5-amino allyl uracil, 8-halo, amino, thio
- H i.
- R 4 , R 5 , and R 6 are each, independently, OR 8 , 0(CH 2 CH 2 O) 1n CH 2 CH 2 OR 8 ; O(CH 2 ) n R 9 ; O(CH 2 ) n OR 9 , H; halo; NH 2 ; NHR 8 ; N(R 8 ) 2 ; NH(CH 2 CH 2 NH) 1n CH 2 CH 2 NHR 9 ; NHC(O)R 8 ; ; cyano; mercapto, SR 8 ; alkyl-thio-alkyl; alkyl, aralkyl, cycloalkyl, aryl, heteroaryl, alkenyl, alkynyl, each of which may be optionally substituted with halo, hydroxy, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino,
- (a preferred Al is chosen from 5'- monophosphate ((HO) 2 (O)P-O-5'), 5 '-diphosphate ((HO) 2 (O)P-O-P(HO)(O)-O-5') 5 5'- triphosphate ((HO) 2 (O)P-O-(HO)(O)P-O-P(HO)(O)-O-S'), 5'-guanosine cap (7-methylated or non-methylated) (7m-G-O-5'-(HO)(O)P-O-(HO)(O)P-O-P(HO)(O)-O-5'), 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N-0-5' -(HO)(O)P-O-
- 5'-alpha-thiotriphosphate 5'-gamma-thiotriphosphate, etc.
- 5 '-phosphoramidates ((HO) 2 (O)P-NH-5 ' , (HO)(NH 2 )(O)P-O-5 '), 5 '-alkylphosphonates
- a 2 is:
- a 3 is:
- W 1 is OH, (CH 2 ) n R 10 , (CH 2 ) n NHR 10 , (CH 2 ) n OR 10 , (CH 2 ) n SR 10 ; O(CH 2 ) n R 10 ; O(CH 2 ) n OR 10 , O(CH 2 ) n NR 10 , 0(CH 2 ) n SR 10 ; O(CH 2 ) n SS(CH 2 ) n OR 10 , 0(CH 2 ) n C(O)OR 10 , NH(CH 2 ) n R 10 ; NH(CH 2 ) n NR 10 ;NH(CH 2 ) n OR 10 , NH(CH 2 ) n SR 10 ; S(CH 2 ) n R 10 , S(CH 2 ) n NR 10 , S(CH 2 ) n OR 10 , S(CH 2 ) n SR 10 O(CH 2 CH 2 O) m CH 2
- X 1 , X 2 , X 3 , and X 4 are each, independently, O or S.
- Y 1 , Y 2 , Y 3 , and Y 4 are each, independently, OH, O “ , OR 8 , S, Se, BH 3 " , H, NHR 9 , N(R 9 ) 2 alkyl, cycloalkyl, aralkyl, aryl, or heteroaryl, each of which may be optionally substituted.
- Z 1 , Z 2 , and Z 3 are each independently O, CH 2 , NH, or S.
- Z 4 is OH, (CH 2 ) n R 10 , (CH 2 ) n NHR 10 , (CH 2 ) n OR 10 , (CH 2 ) n SR 10 ; O(CH 2 ) n R 10 ; O(CH 2 ) n OR 10 , O(CH 2 ) n NR 10 , O(CH 2 ) n SR 10 , O(CH 2 ) n SS(CH 2 ) n OR 10 , O(CH 2 ) n C(O)OR 10 ; NH(CH 2 ) n R 10 ; NH(CH 2 ) n NR 10 ;NH(CH 2 ) n OR 10 , NH(CH 2 ) n SR 10 ; S(CH 2 ) n R 10 , S(CH 2 ) n NR 10 , S(CH 2 ) n OR 10 , S(CH 2 ) n SR 10 0(CH 2 CH 2 O) 1n CH 2 CH
- X is 5-100, chosen to comply with a length for an oligonucleotide agent described herein.
- R 7 is H; or is together combined with R 4 , R 5 , or R 6 to form an [-0-CH 2 -] covalently bound bridge between the sugar 2' and 4' carbons.
- R 8 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, amino acid, or sugar;
- R 9 is
- R 10 is H; fluorophore (pyrene, TAMRA, fluorescein, Cy3 or Cy5 dyes); sulfur, silicon, boron or ester protecting group; intercalating agents (e.g. acridities), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4,texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g.
- lipohilic carriers cholesterol, cholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3 -propanediol, heptadecyl group, palmitic acid,myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG] 2 , polyamino; alkyl
- biotin e.g., aspirin, vitamin E, folic acid
- synthetic ribonucleases e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles
- M is 0-1,000,000, and n is 0-20.
- Q is a spacer selected from the group consisting of abasic sugar, amide, carboxy, oxyamine, oxyimine, thioether, disulfide, thiourea, sulfonamide, or morpholino, biotin or fluorescein reagents.
- Preferred oligonucleotide agents in which the entire phosphate group has been replaced have the following structure (see Formula 3 below):
- a 10 -A 40 is L-G-L; A 10 and/or A 40 may be absent, in which L is a linker, wherein one or both L may be present or absent and is selected from the group consisting of CH 2 (CH 2 ) g ; N(CH 2 ) g ; O(CH 2 ) g ; S(CH 2 ) g .
- G is a functional group selected from the group consisting of siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino .
- R 10 , R 20 , and R 30 are each, independently, H 5 (i.e.
- abasic nucleotides adenine, guanine, cytosine and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidine, isoguanisine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 5- halouracil, 5-(2-aminopropyl)uracil, 5-amino allyl uracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guan
- R 40 , R 50 , and R 60 are each, independently, OR 8 , 0(CH 2 CH 2 O) 1n CH 2 CH 2 OR 8 ; O(CH 2 ) n R 9 ; O(CH 2 ) n OR 9 , H; halo; NH 2 ; NHR 8 ; N(R 8 ) 2 ; NH(CH 2 CH 2 NH) 1n CH 2 CH 2 R 9 ; NHC(O)R 8 ;; cyano; mercapto, SR 7 ; alkyl-thio-alkyl; alkyl, aralkyl, cycloalkyl, aryl, heteroaryl, alkenyl, alkynyl, each of which may be optionally substituted with halo, hydroxy, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, heterocycl
- X is 5-100 or chosen to comply with a length for an oligonucleotide agent described herein.
- R 70 is H; or is together combined with R 40 , R 50 , or R 60 to form an [-0-CH 2 -] covalently bound bridge between the sugar 2' and 4' carbons.
- R 8 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, amino acid, or sugar; and R 9 is NH 2 , alkylamino, dialkylamino, heterocyclyl, arylamino, diaryl amino, heteroaryl amino, diheteroaryl amino, or amino acid.
- M is 0-1,000,000, n is 0-20, and g is 0-2.
- Preferred nucleoside surrogates have the following structure (see Formula 4 below):
- S is a nucleoside surrogate selected from the group consisting of mophilino, cyclobutyl, pyrrolidine and peptide nucleic acid.
- L is a linker and is selected from the group consisting of CH 2 (CH 2 ) g ; N(CH 2 ) g ; O(CH 2 ) g ; S(CH 2 ) g ; -C(O)(CH 2 ) n -or may be absent.
- M is an amide bond; sulfonamide; sulfmate; phosphate group; modified phosphate group as described herein; or may be absent.
- R 100 , R 200 , and R 300 are each, independently, H (i.e., abasic nucleotides), adenine, guanine, cytosine and uracil, inosine, thymine, xanthine, hypoxanthine, nubularine, tubercidine, isoguanisine, 2-arninoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 5- halouracil, 5-(2-aminopropyl)uracil, 5-amino allyl uracil, 8-halo, amino, thiol, thio
- X is 5-100, or chosen to comply with a length for an oligonucleotide agent described herein; and g is 0-2.
- Nuclease resistant monomers The monomers and methods described herein can be used to prepare an oligonucleotide agent, that incorporates a nuclease resistant monomer (NRM).
- NRM nuclease resistant monomer
- An oligonucleotide agent can include monomers which have been modifed so as to inhibit degradation, e.g., by nucleases, e.g., endonucleases or exonucleases, found in the body of a subject. These monomers are referred to herein as NRMs, or nuclease resistance promoting monomers or modifications.
- oligonucleotide agent e.g., the ability to interact with a protein, e.g., a transport protein, e.g., serum albumin, or a member of the RISC (RNA-induced Silencing Complex), or the ability of the first and second sequences to form a duplex with one another or to form a duplex with another sequence, e.g., a target molecule.
- a protein e.g., a transport protein, e.g., serum albumin, or a member of the RISC (RNA-induced Silencing Complex)
- RISC RNA-induced Silencing Complex
- modifications of the sugar, base, and/or phosphate backbone in an oligonucleotide agent can enhance endonuclease and exonuclease resistance, and can enhance interactions with transporter proteins and one or more of the functional components of the RISC complex.
- Preferred modifications are those that increase exonuclease and endonuclease resistance and thus prolong the half-life of the oligonucleotide agent prior to interaction with the RISC complex, but at the same time do not render the oligonucleotide agent resistant to endonuclease activity in the RISC complex.
- preferred NElMs include nucleotide dimers with an enriched for or having a pure chiral form of a modified phosphate group containing a heteroatom at the nonbridging position, e.g., Sp or Rp, at the position X, where this is the position normally occupied by the oxygen.
- the atom at X can also be S, Se, Nr 2 , or Br 3 .
- X is S
- enriched or chirally pure Sp linkage is preferred.
- Enriched means at least 70, 80, 90, 95, or 99% of the preferred form.
- NRMs are discussed in more detail below; (ii) attachment of one or more cationic groups to the sugar, base, and/or the phosphorus atom of a phosphate or modified phosphate backbone moiety.
- preferred NRMs include monomers at the terminal position derivatized at a cationic group.
- this NRM is preferably not used at the 5' end of the agent.
- the group should be attached at a position on the base which minimizes interference with H bond formation and hybridization, e.g., away from the face which interacts with the complementary base on the other strand, e.g, at the 5' position of a pyrimidine or a 7-position of a purine.
- L-RNA, 2' -5' linkages, inverted linkages, a-nucleosides include: L nucleosides and dimeric nucleotides derived from L-nucleosides; 2'-5' phosphate, non-phosphate and modified phosphate linkages (e.g., thiophosphates, phosphoramidates and boronophosphates); dimers having inverted linkages, e.g., 3'-3' or 5'-5' linkages; monomers having an alpha linkage at the 1' site on the sugar, e.g., the structures described herein having an alpha linkage;
- preferred NRM's can include e.g., a targeting moiety or a conjugated ligand described herein, e.g., conjugated with the monomer, e.g., through the sugar, base, or backbone; (vi) abasic linkages.
- preferred NRM' s can include an abasic monomer, e.g., an abasic monomer as described herein (e.g., a nucleobaseless monomer); an aromatic or heterocyclic or polyheterocyclic aromatic monomer as described herein; and
- preferred NRM' s include monomers, preferably at the terminal position, e.g., the 5' position, in which one or more atoms of the phosphate group are derivatized with a protecting group, which protecting group or groups, are removed as a result of the action of a component in the subject's body, e.g, a carboxyesterase or an enzyme present in the subject's body.
- a phosphate prodrug in which a carboxy esterase cleaves the protected molecule resulting in the production of a thioate anion which attacks a carbon adjacent to the O of a phosphate and resulting in the production of an unprotected phosphate.
- NRM modifications can be introduced into an oligonucleotide agent or into a sequence of an oligonucleotide agent.
- An NRM modification can be used more than once in a sequence or in an oligonucleotide agent. As some NRM' s interfere with hybridization the total number incorporated, should be such that acceptable levels of oligonucleotide agent/target RNA duplex formation are maintained.
- a modification can include the alteration, e.g., replacement, of one or both of the non- linking (X and Y) phosphate oxygens and/or of one or more of the linking (W and Z) phosphate oxygens.
- Formula X depicts a phosphate moiety linking two sugar/sugar surrogate-base moieties, SB 1 and SB 2 .
- one of the non-linking phosphate oxygens in the phosphate backbone moiety can be replaced by any one of the following: S, Se, BR 3 (R is hydrogen, alkyl, aryl, etc.), C (i.e., an alkyl group, an aryl group, etc.), H, NR 2 (R is hydrogen, alkyl, aryl, etc.), or OR (R is alkyl or aryl).
- S, Se R is hydrogen, alkyl, aryl, etc.
- C i.e., an alkyl group, an aryl group, etc.
- H NR 2
- OR R is alkyl or aryl
- the phosphorus atom in an unmodified phosphate group is achiral.
- the stereogenic phosphorus atom can possess either the "R" configuration (herein Rp) or the "S” configuration (herein Sp).
- Rp the "R" configuration
- Sp the "S” configuration
- oligonucleotide agents have phosphate groups in which a phosphate non-linking oxygen has been replaced by another atom or group of atoms, may contain a population of stereogenic phosphorus atoms in which at least about 50% of these atoms ⁇ e.g., at least about 60% of these atoms, at least about 70% of these atoms, at least about 80% of these atoms, at least about 90% of these atoms, at least about 95% of these atoms, at least about 98% of these atoms, at least about 99% of these atoms) have the Sp configuration.
- oligonucleotide agents having phosphate groups in which a phosphate non-linking oxygen has been replaced by another atom or group of atoms may contain a population of stereogenic phosphorus atoms in which at least about 50% of these atoms (e.g., at least about 60% of these atoms, at least about 70% of these atoms, at least about 80% of these atoms, at least about 90% of these atoms, at least about 95% of these atoms, at least about 98% of these atoms, at least about 99% of these atoms) have the Rp configuration
- the population of stereogenic phosphorus atoms may have the Sp configuration and may be substantially free of stereogenic phosphorus atoms having the Rp configuration
- the population of stereogenic phosphorus atoms may have the Rp configuration and may be substantially free of stereogenic phosphorus atoms having the Sp configuration.
- the phrase "substantially free of stereogenic phosphorus atoms having the Rp configuration” means that moieties containing stereogenic phosphorus atoms having the Rp configuration cannot be detected by conventional methods known in the art (chiral HPLC, 1 H NMR analysis using chiral shift reagents, etc.).
- the phrase "substantially free of stereogenic phosphorus atoms having the Sp configuration” means that moieties containing stereogenic phosphorus atoms having the Sp configuration cannot be detected by conventional methods known in the art (chiral HPLC, 1 H NMR analysis using chiral shift reagents, etc.).
- modified oligonucleotide agents contain a phosphorothioate group, i.e., a phosphate groups in which a phosphate non-linking oxygen has been replaced by a sulfur atom
- the population of phosphorothioate stereogenic phosphorus atoms may have the Sp configuration and be substantially free of stereogenic phosphorus atoms having the Rp configuration.
- Phosphorothioates may be incorporated into oligonucleotide agents using dimers e.g., formulas X-I and X-2.
- the former can be used to introduce phosphorothioate
- Y can be 2-cyanoethoxy
- W and Z can be O
- R 2 - can be, e.g., a substituent that can impart the C-3 endo configuration to the sugar (e.g., OH, F, OCH 3 )
- DMT is dimethoxytrityl
- "BASE" can be a natural, unusual, or a universal base.
- X-I and X-2 can be prepared using chiral reagents or directing groups that can result in phosphorothioate-containing dimers having a population of stereogenic phosphorus atoms having essentially only the Rp configuration (i.e., being substantially free of the Sp configuration) or only the Sp configuration (i.e., being substantially free of the Rp configuration).
- dimers can be prepared having a population of stereogenic phosphorus atoms in which about 50% of the atoms have the Rp configuration and about 50% of the atoms have the Sp configuration.
- Dimers having stereogenic phosphorus atoms with the Rp configuration can be identified and separated from dimers having stereogenic phosphorus atoms with the Sp configuration using e.g., enzymatic degradation and/or conventional chromatography techniques.
- Modifications can also include attachment of one or more cationic groups to the sugar, base, and/or the phosphorus atom of a phosphate or modified phosphate backbone moiety.
- a cationic group can be attached to any atom capable of substitution on a natural, unusual or universal base.
- a preferred position is one that does not interfere with hybridization, i.e., does not interfere with the hydrogen bonding interactions needed for base pairing.
- a cationic group can be attached e.g., through the C2' position of a sugar or analogous position in a cyclic or acyclic sugar surrogate.
- Modifications can also include the incorporation of nonphosphate linkages at the 5' and/or 3' end of a strand.
- nonphosphate linkages which can replace the phosphate group include methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.
- Preferred replacements include the methyl phosphonate and hydroxylamino groups.
- 3 '-bridging thiophosphates and 5 '-bridging thiophosphates; locked-RNA, 2'-5' likages, inverted linkages, ⁇ -nucleosides; conjugate groups; abasic linkages; and 5'-phosphonates and 5 '-phosphate prodrugs are also linkages that can be included in oligonucleotide agents.
- modifications can include replacement of one of the bridging or linking phosphate oxygens in the phosphate backbone moiety (W and Z). Unlike the situation where only one of X or Y is altered, the phosphorus center in the phosphorodithioates is achiral which precludes the formation of oligonucleotide agents containing a stereogenic phosphorus atom.
- Modifications can also include linking two sugars via a phosphate or modified phosphate group through the 2' position of a first sugar and the 5 ' position of a second sugar. Also contemplated are inverted linkages in which both a first and second sugar are eached linked through the respective3' positions.
- Modified RNA's can also include "abasic" sugars, which lack a nucleobase at C-I'.
- the sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose.
- a modified oligonucleotide agent can include nucleotides containing e.g., arabinose, as the sugar, hi another subset of this modification, the natural, unusual, or universal base may have the ⁇ - configuration. Modifcations can also include L-RNA.
- the prodrug groups may be decomposed via reaction first with carboxy esterases. The remaining ethyl thiolate group via intramolecular SN2 displacement can depart as episulfide to afford the underivatized phosphate group.
- Modification can also include the addition of conjugating groups described elsewhere herein, which are prefereably attached to an oligonucleotide agent through any amino group available for conjugation.
- Nuclease resistant modifications include some which can be placed only at the terminus and others which can go at any position. Generally, these modifications can inhibit hybridization so it is preferably to use them only in terminal regions, and preferable to not use them at the cleavage site or in the cleavage region of a sequence. Modifications which interfere with or inhibit endonuclease cleavage should not be inserted in the region of an oligonucleotide agent which is subject to RISC mediated cleavage, e.g., the cleavage site or the cleavage region.
- cleavage site refers to the nucleotide on either side of the cleavage site on the target or on the oligonucleotide agent strand which hybridizes to it.
- Cleavage region means an nucleotide with 1, 2, or 3 nucletides of the cleave site, in either direction.) Such modifications can be introduced into the terminal regions, e.g., at the terminal position or with 2, 3, 4, or 5 positions of the terminus.
- An oligonucleotide agent can have the following: an NEUVI modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 3' end; an NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 5' end (5' end NRM modifications are preferentially not at the terminus but rather at a position 1, 2, 3, 4, 5 , or 6 away from the 5' terminus of the oligonucleotide agent); an NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 3' end and which has a NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 5' end; an NRM modification at the cleavage site or in the cleavage region; an NRM modification at the cleavage site or in the cleavage region and one or more of an NEUVI modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 3' end; an NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 5' end (5' end NRM
- NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 3' end an NRM modification at or within 1, 2, 3, 4, 5 , or 6 positions from the 5' end, or NRM modifications at or within 1, 2, 3, 4, 5 , or 6 positions from both the 3' and the 5' end(5' end NRM modifications are preferentially not at the terminus but rather at a position 1, 2, 3, 4, 5 , or 6 away from the 5' terminus of the oligonucleotide agent).
- an aspect of the invention features an oligonucleotide agent that includes a secondary hydroxyl group, which can increase efficacy and/or confer nuclease resistance to the agent.
- Nucleases e.g., cellular nucleases, can hydrolyze nucleic acid phosphodiester bonds, resulting in partial or complete degradation of the nucleic acid.
- the secondary hydroxy group confers nuclease resistance to an oligonucleotide agent by rendering the oligonucleotide agent less prone to nuclease degradation relative to an oligonucleotide agent that lacks the modification. While not wishing to be bound by theory, it is believed that the presence of a secondary hydroxyl group on the oligonucleotide agent can act as a structural mimic of a 3' ribose hydroxyl group, thereby causing it to be less susceptible to degradation.
- the secondary hydroxyl group refers to an "OH" radical that is attached to a carbon atom substituted by two other carbons and a hydrogen.
- the secondary hydroxyl group that confers nuclease resistance as described above can be part of any acyclic carbon-containing group.
- the hydroxyl may also be part of any cyclic carbon-containing group, and preferably one or more of the following conditions is met (1) there is no ribose moiety between the hydroxyl group and the terminal phosphate group or (2) the hydroxyl group is not on a sugar moiety which is coupled to a base.
- the hydroxyl group is located at least two bonds (e.g., at least three bonds away, at least four bonds away, at least five bonds away, at least six bonds away, at least seven bonds away, at least eight bonds away, at least nine bonds away, at least ten bonds away, etc.) from the terminal phosphate group phosphorus of the oligonucleotide agent. In preferred embodiments, there are five intervening bonds between the terminal phosphate group phosphorus and the secondary hydroxyl group.
- Preferred oligonucleotide agent delivery modules with five intervening bonds between the terminal phosphate group phosphorus and the secondary hydroxyl group have the following structure (see formula Y below):
- A is an oligonucleotide agent, including any oligonucleotide agent described herein.
- the oligonucleotide agent may be connected directly or indirectly (e.g., through a spacer or linker) to "W" of the phosphate group.
- abasic sugars amide, carboxy, amine, oxyamine, oxyimine, thioether, disulfide, thiourea, sulfonamide, or morpholino, or biotin and fluorescein reagents.
- the oligonucleotide agents can have a terminal phosphate group that is unmodified (e.g., W, X, Y, and Z are O) or modified.
- W and Z can be independently NH, O, or S; and
- X and Y can be independently S, Se, BH 3 " , C 1 -C 6 alkyl, C 6 -C 1 O aryl, H, O, O " , alkoxy or amino (including alkylamino, arylamino, etc.).
- W, X and Z are O and Y is S.
- R 1 and R 3 are each, independently, hydrogen; or C 1 -C 100 alkyl, optionally substituted with hydroxyl, amino, halo, phosphate or sulfate and/or may be optionally inserted with N, O, S, alkenyl or alkynyl.
- R 2 is hydrogen; C 1 -C 100 alkyl, optionally substituted with hydroxyl, amino, halo, phosphate or sulfate and/or may be optionally inserted with N, O, S, alkenyl or alkynyl; or, when n is 1 , R 2 may be taken together with with R 4 or R 6 to form a ring of 5-12 atoms.
- R 4 is hydrogen; C 1 -C 100 alkyl, optionally substituted with hydroxyl, amino, halo, phosphate or sulfate and/or may be optionally inserted with N, O, S, alkenyl or alkynyl; or, when n is 1, R 4 may be taken together with with R 2 or R 5 to form a ring of 5-12 atoms.
- R 5 is hydrogen, C 1 -C 100 alkyl optionally substituted with hydroxyl, amino, halo, phosphate or sulfate and/or may be optionally inserted with N, O, S, alkenyl or alkynyl; or, when n is 1 , R 5 may be taken together with with R 4 to form a ring of 5-12 atoms.
- R 6 is hydrogen, C 1 -C 10O alkyl, optionally substituted with hydroxyl, amino, halo, phosphate or sulfate and/or may be optionally inserted with N, O, S, alkenyl or alkynyl, or, when n is 1 , R 6 may be taken together with with R 2 to form a ring of 6- 10 atoms;
- R 7 is hydrogen, C 1 -C 100 alkyl, or C(O)(CH 2 ) q C(O)NHR 9 ;
- T is hydrogen or a functional group;
- n and q are each independently 1-100;
- R 8 is C 1 -C 10 alkyl or C 6 -C 10 aryl; and
- R 9 is hydrogen, Cl-ClO alkyl, C6-C10 aryl or a solid support agent.
- Preferred embodiments may include one of more of the following subsets of oligonucleotide agent delivery modules.
- A can be connected directly or indirectly through a terminal 3' or 5' ribose sugar carbon of the oligonucleotide agent.
- X, W, and Z are O and Y is
- n is 1, and R 2 and R 6 are taken together to form a ring containing six atoms and R 4 and R 5 are taken together to form a ring containing six atoms.
- the ring system is a trans-decalin.
- the Oligonucleotide agent delivery module of this subset can include a compound of Formula (Y-I):
- the functional group can be, for example, a targeting group (e.g., a steroid or a carbohydrate), a reporter group (e.g., a fluorophore), or a label (an isotopically labelled moiety).
- a targeting group e.g., a steroid or a carbohydrate
- a reporter group e.g., a fluorophore
- a label an isotopically labelled moiety
- the targeting group can further include protein binding agents, endothelial cell targeting groups (e.g., RGD peptides and mimetics), cancer cell targeting groups (e.g., folate Vitamin B12, Biotin), bone cell targeting groups (e.g., bisphosphonates, polyglutamates, polyaspartates), multivalent mannose (for e.g., macrophage testing), lactose, galactose, N-acetyl-galactosamine, monoclonal antibodies, glycoproteins, lectins, melanotropin, or thyrotropin.
- endothelial cell targeting groups e.g., RGD peptides and mimetics
- cancer cell targeting groups e.g., folate Vitamin B12, Biotin
- bone cell targeting groups e.g., bisphosphonates, polyglutamates, polyaspartates
- multivalent mannose for e.g., macrophage testing
- lactose galactose
- oligonucleotide agent e.g., conjugated oligonucleotide agent described herein, that can be used with a drug delivery conjugate or module.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05786618.8A EP1791567B1 (en) | 2004-08-10 | 2005-08-10 | Chemically modified oligonucleotides |
CA2576233A CA2576233C (en) | 2004-08-10 | 2005-08-10 | Conjugate comprising an antagomir and a ligand |
JP2007525790A JP5192234B2 (en) | 2004-08-10 | 2005-08-10 | Chemically modified oligonucleotide |
AU2005272816A AU2005272816B2 (en) | 2004-08-10 | 2005-08-10 | Chemically modified oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60070304P | 2004-08-10 | 2004-08-10 | |
US60/600,703 | 2004-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006020768A2 true WO2006020768A2 (en) | 2006-02-23 |
WO2006020768A3 WO2006020768A3 (en) | 2007-07-05 |
Family
ID=35908139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/028550 WO2006020768A2 (en) | 2004-08-10 | 2005-08-10 | Chemically modified oligonucleotides |
Country Status (6)
Country | Link |
---|---|
US (5) | US7582744B2 (en) |
EP (2) | EP2990410A1 (en) |
JP (1) | JP5192234B2 (en) |
AU (1) | AU2005272816B2 (en) |
CA (1) | CA2576233C (en) |
WO (1) | WO2006020768A2 (en) |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008068047A1 (en) * | 2006-12-05 | 2008-06-12 | Istituto Superiore Di Sanita | Micro rna targeting ets1 |
WO2008089248A2 (en) * | 2007-01-19 | 2008-07-24 | The Board Of Trustees Of The University Of Illinois | Amphiphilic substances and triggered liberation from lipid vesicles |
WO2009073809A2 (en) * | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2009082606A2 (en) * | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
EP2227545A2 (en) * | 2007-11-09 | 2010-09-15 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
US7799554B2 (en) | 2006-03-16 | 2010-09-21 | The Board Of Trustees Of The University Of Illinois | Lateral flow devices |
US7892734B2 (en) | 2005-08-11 | 2011-02-22 | The Board Of Trustees Of The University Of Illinois | Aptamer based colorimetric sensor systems |
US7902353B2 (en) | 2000-06-27 | 2011-03-08 | The Board Of Trustees Of The University Of Illinois | Nucleic acid enzyme biosensors for ions |
US7906320B2 (en) | 2002-05-10 | 2011-03-15 | The Board Of Trustees Of The University Of Illinois | Fluorescence based biosensor |
EP2377873A1 (en) * | 2004-09-24 | 2011-10-19 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
WO2012030745A1 (en) * | 2010-08-30 | 2012-03-08 | Access Pharmaecuticals, Inc | MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS |
US8163708B2 (en) | 2006-04-03 | 2012-04-24 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide |
WO2012059612A1 (en) | 2010-11-04 | 2012-05-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivatives of small interfering rnas and use thereof |
US8288356B2 (en) | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
US8513209B2 (en) | 2007-11-09 | 2013-08-20 | The Board Of Regents, The University Of Texas System | Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8598143B2 (en) | 2003-11-26 | 2013-12-03 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US8729250B2 (en) | 2006-04-03 | 2014-05-20 | Joacim Elmén | Antisense oligonucleotides for inhibition of microRNA-21 |
US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
US8980855B2 (en) | 2009-11-25 | 2015-03-17 | Elitech Holding B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
WO2016170349A1 (en) * | 2015-04-22 | 2016-10-27 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
WO2020069055A1 (en) * | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
US10731157B2 (en) | 2015-08-24 | 2020-08-04 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
WO2020264055A1 (en) * | 2019-06-25 | 2020-12-30 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
AU2020203054B2 (en) * | 2007-12-04 | 2022-03-03 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US11597701B2 (en) | 2017-11-01 | 2023-03-07 | Arrowhead Pharmaceuticals, Inc. | Integrin ligands and uses thereof |
WO2023060238A3 (en) * | 2021-10-08 | 2023-05-11 | Regulus Therapeutics Inc. | Methods and compositions for avoiding off-target effects |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1389209B1 (en) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
US20030134433A1 (en) * | 2002-01-16 | 2003-07-17 | Nanomix, Inc. | Electronic sensing of chemical and biological agents using functionalized nanostructures |
US20070178477A1 (en) * | 2002-01-16 | 2007-08-02 | Nanomix, Inc. | Nanotube sensor devices for DNA detection |
US20060228723A1 (en) * | 2002-01-16 | 2006-10-12 | Keith Bradley | System and method for electronic sensing of biomolecules |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
CA2475003A1 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
US7910594B2 (en) * | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US7948041B2 (en) | 2005-05-19 | 2011-05-24 | Nanomix, Inc. | Sensor having a thin-film inhibition layer |
EP2517730A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US8017762B2 (en) * | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
EP2471921A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
US8153111B2 (en) * | 2004-06-18 | 2012-04-10 | Ceramoptec Industries, Inc. | Photo-triggered release of active substances from dendrimer-photosensitizer complexes |
CN101098854B (en) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | Bivalent linkers and conjugates thereof |
AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
ES2632913T3 (en) * | 2004-08-23 | 2017-09-18 | Sylentis S.A.U. | Treatment with mRNA of eye disorders characterized by elevated intraocular pressure |
EP2302054B1 (en) * | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
CN101175757B (en) * | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | Synthesis and purification of pteroic acid and conjugates thereof |
US8153435B1 (en) | 2005-03-30 | 2012-04-10 | Tracer Detection Technology Corp. | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
PL2002003T3 (en) * | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Gene vector comprising mi-rna |
US9290617B2 (en) * | 2005-07-06 | 2016-03-22 | Molly S. Shoichet | Method of biomolecule immobilization on polymers using click-type chemistry |
CN103893779A (en) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | Multi-drug ligand conjugates |
EP1948240A2 (en) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs and derivatives |
US20090203893A1 (en) * | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
WO2007027775A2 (en) * | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
EP1937312B1 (en) * | 2005-08-30 | 2016-06-29 | Ionis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
WO2007109350A2 (en) * | 2006-03-23 | 2007-09-27 | California Institute Of Technology | Modulation of innate immunity receptors' signaling by micrornas mir-146a and mir-146b |
US20090023221A1 (en) * | 2006-05-19 | 2009-01-22 | Exigon A/S | Oligonucleotide probes useful for detection and analysis of microrna precursors |
WO2008033285A2 (en) * | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
AU2007299804A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | MiR-200 regulated genes and pathways as targets for therapeutic intervention |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
AU2008224988A1 (en) * | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US20110046206A1 (en) * | 2007-06-22 | 2011-02-24 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US20090082297A1 (en) * | 2007-06-25 | 2009-03-26 | Lioy Daniel T | Compositions and Methods for Regulating Gene Expression |
WO2009026576A1 (en) * | 2007-08-23 | 2009-02-26 | Keren Pharmaceuticals | Targeting rna with external guide sequences |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
JP5646997B2 (en) * | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | Novel siRNA structure |
WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
JP5535076B2 (en) | 2007-10-29 | 2014-07-02 | レグルス・セラピューティクス・インコーポレイテッド | Targeted microRNA for treating liver cancer |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
CA2717026A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
EP2268316A4 (en) * | 2008-03-20 | 2011-05-25 | Quark Pharmaceuticals Inc | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
EP2285385A4 (en) * | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | siRNA COMPOUNDS FOR INHIBITING NRF2 |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP2310507A4 (en) * | 2008-07-08 | 2013-03-20 | David Gladstone Inst | Methods and compositions for modulating angiogenesis |
ES2610622T3 (en) * | 2009-03-31 | 2017-04-28 | The General Hospital Corporation | Regulation of miR-33 microRNA in the treatment of cholesterol-related disorders |
WO2010134992A2 (en) * | 2009-05-18 | 2010-11-25 | Chemgenes Corporation | Synthesis labile base protected - modified deoxy & modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis |
WO2010133970A1 (en) | 2009-05-20 | 2010-11-25 | Eth Zurich | Targeting micrornas for metabolic disorders |
EP2440566A4 (en) * | 2009-06-08 | 2013-10-16 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
CA2776568A1 (en) | 2009-11-26 | 2011-06-03 | Quark Pharmaceuticals, Inc. | Sirna compounds comprising terminal substitutions |
KR101718534B1 (en) | 2009-12-09 | 2017-03-22 | 닛토덴코 가부시키가이샤 | MODULATION OF hsp47 EXPRESSION |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
US20130059906A1 (en) * | 2010-02-17 | 2013-03-07 | The Board Of Regents Of The University Of Texas System | Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor |
EP2608812B1 (en) | 2010-08-25 | 2018-08-15 | The General Hospital Corporation | Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism |
DK2629783T3 (en) * | 2010-10-21 | 2015-03-02 | Deutsches Krebsforsch | Changing the targeting of rat parvovirus H-1PV against cancer cells by genetic engineering of the capsid |
KR101913232B1 (en) * | 2010-10-27 | 2018-10-30 | 큐알엔에이, 인크. | Treatment of interferon-related developmental regulator 1(ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
WO2012078536A2 (en) * | 2010-12-06 | 2012-06-14 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
WO2012100142A2 (en) * | 2011-01-20 | 2012-07-26 | Cornell University | Treatments for retinal disorders |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
MY187685A (en) | 2011-04-25 | 2021-10-11 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
US8846633B2 (en) | 2011-11-07 | 2014-09-30 | Taipei Veterans General Hospital | Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microRNA145 |
WO2013071079A1 (en) | 2011-11-09 | 2013-05-16 | President And Fellows Of Harvard College | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
KR102118429B1 (en) | 2012-04-25 | 2020-06-03 | 사노피 | Microrna compounds and methods for modulating mir-21 activity |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
WO2014037686A1 (en) | 2012-09-05 | 2014-03-13 | Sylentis S.A.U. | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
UA116639C2 (en) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Methods for treatment of alport syndrome |
US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
SG11201502896XA (en) | 2012-10-16 | 2015-05-28 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
US10731161B2 (en) | 2013-03-11 | 2020-08-04 | The Johns Hopkins University | Influenza-activated constructs and methods of use thereof |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014140856A2 (en) | 2013-03-15 | 2014-09-18 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
RU2686080C2 (en) | 2013-05-01 | 2019-04-24 | Ионис Фармасьютикалз, Инк. | Compositions and methods |
LT3019619T (en) | 2013-07-11 | 2021-12-10 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2845607A1 (en) * | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
US10202601B2 (en) | 2013-11-22 | 2019-02-12 | Mina Therapeutics Limited | C/EBPα short activating RNA compositions and methods of use |
WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
EP3137476B1 (en) | 2014-04-28 | 2019-10-09 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
KR102366078B1 (en) | 2014-05-01 | 2022-02-21 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compositions and methods for modulating pkk expression |
PE20170010A1 (en) | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF THE COMPLEMENT FACTOR B |
MX2016014102A (en) | 2014-05-01 | 2017-05-03 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating angiopoietin-like 3 expression. |
WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
AU2015289656A1 (en) | 2014-07-16 | 2017-02-16 | Modernatx, Inc. | Circular polynucleotides |
RU2718534C2 (en) | 2015-06-05 | 2020-04-08 | Мираджен Терапьютикс, Инк. | Mir-155 inhibitors for treatment of cutaneous t-cell lymphoma (ctcl) |
PE20180800A1 (en) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | DIACIGLYCEROL ACILTRANSFERASE 2 (DGAT2) MODULATORS |
WO2017049286A1 (en) * | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
CA2998382A1 (en) | 2015-09-24 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Modulators of kras expression |
CN108348478A (en) | 2015-11-06 | 2018-07-31 | Ionis 制药公司 | Apolipoprotein (a) is adjusted to express |
US20190046555A1 (en) | 2015-11-06 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
EP3181698A1 (en) | 2015-12-16 | 2017-06-21 | European Molecular Biology Laboratory (EMBL) | Microrna mir-142 as stem cell marker |
WO2018014041A2 (en) | 2016-07-15 | 2018-01-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
CN109661233A (en) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | The method that oligomeric compound is conjugated |
EP3533868A4 (en) * | 2016-10-31 | 2019-12-11 | Gifu University | Double-stranded nucleic acid molecule, and use thereof |
JOP20190215A1 (en) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | Modulators of pcsk9 expression |
WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
EP3718572A4 (en) | 2017-12-01 | 2021-09-08 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
JP7261494B2 (en) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | Nucleic acids, compositions and complexes containing said nucleic acids, preparation methods and uses |
EP3719128A4 (en) | 2017-12-01 | 2021-10-27 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use |
KR102617947B1 (en) | 2017-12-29 | 2023-12-27 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | Conjugates and their preparation and uses |
MX2020007369A (en) | 2018-01-15 | 2020-10-28 | Ionis Pharmaceuticals Inc | Modulators of dnm2 expression. |
CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
EP4242307A3 (en) | 2018-04-12 | 2023-12-27 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
MX2020011913A (en) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing fxi expression. |
WO2020033748A1 (en) | 2018-08-08 | 2020-02-13 | Arcturus Therapeutics, Inc. | Compositions and agents against nonalcoholic steatohepatitis |
EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
TW202023573A (en) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Modulators of pnpla3 expression |
WO2020063198A1 (en) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | Sirna conjugate, preparation method therefor and use thereof |
EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
EP4017539A1 (en) | 2019-08-19 | 2022-06-29 | MiNA Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
TW202140787A (en) | 2020-02-28 | 2021-11-01 | 美商Ionis製藥公司 | Compounds and methods for modulating smn2 |
EP4136092A4 (en) | 2020-11-18 | 2023-10-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
AU2022246144A1 (en) | 2021-03-26 | 2023-09-21 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
WO2023034561A2 (en) * | 2021-09-02 | 2023-03-09 | Vanderbilt University | Lipophilic oligonucleotide conjugates |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
TW202400787A (en) | 2022-03-16 | 2024-01-01 | 美商安彼瑞可股份有限公司 | Galnac compositions for improving sirna bioavailability |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5366878A (en) | 1990-02-15 | 1994-11-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5508270A (en) | 1993-03-06 | 1996-04-16 | Ciba-Geigy Corporation | Nucleoside phosphinate compounds and compositions |
WO1996037194A1 (en) | 1995-05-26 | 1996-11-28 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
WO2000044895A1 (en) | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a defined gene |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2002044321A2 (en) | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
ATE124999T1 (en) | 1985-03-15 | 1995-07-15 | Antivirals Inc | POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS. |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
BR9106702A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | ANALOG OF OLIGONUCLEOTIDEOS AND PROCESSES TO MODULATE THE PRODUCTION OF A PROTEIN BY AN ORGANISM AND TO TREAT AN ORGANISM |
EP0547142A1 (en) * | 1990-08-28 | 1993-06-23 | Epoch Pharmaceuticals, Inc. | Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5652359A (en) * | 1993-12-02 | 1997-07-29 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing n-methyl thiolated bases having antiviral activity |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
EP1012331B1 (en) * | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
EP2385122B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
EP1549352A4 (en) * | 2002-05-06 | 2005-07-27 | Nucleonics Inc | Methods for delivery of nucleic acids |
CN1156336C (en) | 2002-07-12 | 2004-07-07 | 清华大学 | Preparation method of titanium dioxide film photocatalyst loaded on surface of flexible base material |
WO2004011647A1 (en) * | 2002-07-26 | 2004-02-05 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
JP4939055B2 (en) * | 2002-11-13 | 2012-05-23 | トマス ジェファソン ユニバーシティ | Compositions and methods for diagnosis and treatment of cancer |
ATE479752T1 (en) | 2003-03-07 | 2010-09-15 | Alnylam Pharmaceuticals Inc | THERAPEUTIC COMPOSITIONS |
CA2533701A1 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
-
2005
- 2005-08-10 AU AU2005272816A patent/AU2005272816B2/en active Active
- 2005-08-10 EP EP15002237.4A patent/EP2990410A1/en not_active Withdrawn
- 2005-08-10 EP EP05786618.8A patent/EP1791567B1/en active Active
- 2005-08-10 JP JP2007525790A patent/JP5192234B2/en active Active
- 2005-08-10 US US11/200,703 patent/US7582744B2/en active Active
- 2005-08-10 WO PCT/US2005/028550 patent/WO2006020768A2/en active Application Filing
- 2005-08-10 CA CA2576233A patent/CA2576233C/en active Active
-
2009
- 2009-07-02 US US12/497,262 patent/US8404862B2/en active Active
- 2009-09-17 US US12/561,529 patent/US8017763B2/en active Active
-
2012
- 2012-10-19 US US13/656,365 patent/US8957223B2/en active Active
-
2014
- 2014-12-24 US US14/582,284 patent/US9453222B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5366878A (en) | 1990-02-15 | 1994-11-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US5508270A (en) | 1993-03-06 | 1996-04-16 | Ciba-Geigy Corporation | Nucleoside phosphinate compounds and compositions |
WO1996037194A1 (en) | 1995-05-26 | 1996-11-28 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
WO2000044895A1 (en) | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a defined gene |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2002044321A2 (en) | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
Non-Patent Citations (34)
Title |
---|
AN, H ET AL., J. ORG. CHEM., vol. 66, 2001, pages 2789 - 2801 |
BEAUCAGE, S. L.; IYER, R. P., TETI-AHEDROII, vol. 49, 1993, pages 6123 - 6194 |
BEAUCAGE, S. L; IYER, R. P., TETRAHEDRON, vol. 48, 1992, pages 2223 - 2311 |
BERGER, M.; WU. Y.; OGAWA, A. K.; MCMINN, D. L.; SCHULTZ, P. G.; ROMESBERG, F. E., NUCLEIC ACIDS RES., vol. 28, 2000, pages 2911 - 2914 |
BROTSCHI, C.; HABERLI, A.; LEUMANN, C, J., ANGEW, CHEM, INT. ED., vol. 40, 2001, pages 3012 - 3014 |
CROSSTICK ET AL., TETRAHEDRON LETT., vol. 30, 1989, pages 4693 |
EIS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 102, 2005, pages 3627 - 3632 |
FISCHE ET AL., BIOCONJUGATE. CHEM., vol. 12, 2001, pages 825 |
GANTE, SYNTHESIS, vol. 1989, pages 405 - 413 |
GREENE, T.W.: "Protective Groups in Organic Synthesis", 1981, JOHN WILEY AND SONS |
GUCKIAN, K. M.; MORALES, J. C.; KOOL, E. T, J ORG. CHEM., vol. 63, 1998, pages 9652 - 9656 |
LAN, T.; MCLAUGHLIN, L. W. J., AIN. CHEM. SOC., vol. 122, 2000, pages 6512 - 13 |
LANGEL,: "Cell Penetrating Peptides: Processes and Applications, Langel", 2002, CRC PRESS |
LINDGREN ET AL., TRENDS PHARMACOL. SCI., vol. 21, 2000, pages 99 |
LIU, D.; MORAN, S.; KOOL, E. T., CHEM. BIOI., vol. 199, pages 919 - 926 |
LOAKES, D.: "Survey and Summary: The Applications of Universal DNA base analogues", NUCLEIC ACID RESEARCH, vol. 29, 2001, pages 2437 |
M. J. GAIT,: "Oligonucleotide synthesis, a practical approach", 1984, IRL PRESS |
MANOHARAN: "Antisense Drug Technology", 2001, MARCEL DEKKER, INC., article "Oligonucleotide Conjugates in Antisense Technology" |
MARTIN, P., HELV. CHIM. ACTA, vol. 78, 1995, pages 486 - 504 |
MATRAY, T, J.; KOOL, E. T., J AM. CHEM. SOC., vol. 120, 1998, pages 6191 - 6192 |
MCMINN, D. L.; OGAWA. A. K.; WU, Y.; LIU, J.; SCHULTZ, P. G.; ROMESBERG, F. E., J. AM. CHEM. SOC., vol. 121, 1999, pages 11585 - 11586 |
METZLER ET AL., GENES CHROMOSOM, CANCER, vol. 39, 2004, pages 167 - 169 |
MORALES, J. C.; KOOL, E. T., BIOCHEMISTRY, vol. 39, 2000, pages 2626 - 2632 |
MORAN, S.; REN, R. X.-F.; RUMNEY IV, S.; KOOL, E. T., J. AM. CHEM. SOC., vol. 119, 1997, pages 2056 - 2057 |
OGAWA, A. K.; WU, Y.; MCMINN, D. L.; LIU, J.; SCHULTZ, P. G.; ROMESBERG, F. E., J. AM. CHEM. SOC., vol. 122, 2000, pages 3274 - 3287 |
OGAWA, A. K.; WU. Y.; BERGER, M.; SCHULTZ, P. G.; ROMESBERG, F. E., J. AM. CHEM. SOC., vol. 122, 2000, pages 8803 - 8804 |
See also references of EP1791567A4 |
SHINGARA ET AL., AMBION TECHNOTES, vol. 11, no. 6, 2005 |
SPROAT ET AL., NUCLEOSIDES NUCLEOTIDES, vol. 7, 1988, pages 651 |
TAE, E. L.; WU, Y.; XIA, G.; SCHULTZ, P. G.; ROMESBERG, F. E., J. AIN. CHEM, SOC., vol. 123, 2001, pages 7439 - 7440 |
TRUFERT ET AL., TETRAHEDRON, vol. 52, 1996, pages 3005 |
WANDER ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 13382 |
WEIZMAN, H.; TOR, Y., J. AM. CHEM. SOC., vol. 123, 2001, pages 3375 - 3376 |
WU, Y.; OGAWA, A. K.; BERGER, M.;; MCMINN, D. L.; SCHULTZ, P. G.; ROMESBERG, F. E., J. AM. CHEM. SOC., vol. 122, 2000, pages 7621 - 7632 |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7902353B2 (en) | 2000-06-27 | 2011-03-08 | The Board Of Trustees Of The University Of Illinois | Nucleic acid enzyme biosensors for ions |
US8043802B2 (en) | 2002-05-10 | 2011-10-25 | The Board Of Trustees Of The University Of Illinois | Fluorescence based biosensor |
US7906320B2 (en) | 2002-05-10 | 2011-03-15 | The Board Of Trustees Of The University Of Illinois | Fluorescence based biosensor |
US11359196B2 (en) | 2003-11-26 | 2022-06-14 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US8685946B2 (en) | 2003-11-26 | 2014-04-01 | Universiy of Massachusetts | Sequence-specific inhibition of small RNA function |
US9334497B2 (en) | 2003-11-26 | 2016-05-10 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
US8598143B2 (en) | 2003-11-26 | 2013-12-03 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
EP2982754A1 (en) * | 2004-09-24 | 2016-02-10 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of apob and uses thereof |
EP2377873A1 (en) * | 2004-09-24 | 2011-10-19 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
US7892734B2 (en) | 2005-08-11 | 2011-02-22 | The Board Of Trustees Of The University Of Illinois | Aptamer based colorimetric sensor systems |
US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US7799554B2 (en) | 2006-03-16 | 2010-09-21 | The Board Of Trustees Of The University Of Illinois | Lateral flow devices |
US8729250B2 (en) | 2006-04-03 | 2014-05-20 | Joacim Elmén | Antisense oligonucleotides for inhibition of microRNA-21 |
US8163708B2 (en) | 2006-04-03 | 2012-04-24 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide |
WO2008068047A1 (en) * | 2006-12-05 | 2008-06-12 | Istituto Superiore Di Sanita | Micro rna targeting ets1 |
WO2008089248A3 (en) * | 2007-01-19 | 2009-05-28 | Univ Illinois | Amphiphilic substances and triggered liberation from lipid vesicles |
WO2008089248A2 (en) * | 2007-01-19 | 2008-07-24 | The Board Of Trustees Of The University Of Illinois | Amphiphilic substances and triggered liberation from lipid vesicles |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
US10131907B2 (en) | 2007-04-23 | 2018-11-20 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
US8288356B2 (en) | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
US10450564B2 (en) | 2007-10-04 | 2019-10-22 | Roche Innovation Center Copenhagen A/S | Micromirs |
US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
US8906871B2 (en) | 2007-10-04 | 2014-12-09 | Santaris Pharma A/S | MicromiRs |
EP2227545A2 (en) * | 2007-11-09 | 2010-09-15 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
US8513209B2 (en) | 2007-11-09 | 2013-08-20 | The Board Of Regents, The University Of Texas System | Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair |
AU2008323970B2 (en) * | 2007-11-09 | 2014-05-08 | Isis Pharmaceuticals, Inc. | Modulation of Factor 7 expression |
US9078919B2 (en) | 2007-11-09 | 2015-07-14 | The Board Of Regents, The University Of Texas System | Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair |
EP3000884A1 (en) * | 2007-11-09 | 2016-03-30 | Ionis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
EP4223299A3 (en) * | 2007-12-04 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8106022B2 (en) | 2007-12-04 | 2012-01-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
AU2008340354B2 (en) * | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
AU2008333811B2 (en) * | 2007-12-04 | 2014-05-01 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
JP2018029599A (en) * | 2007-12-04 | 2018-03-01 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8507455B2 (en) | 2007-12-04 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
JP2014139232A (en) * | 2007-12-04 | 2014-07-31 | Alnylam Pharmaceuticals Inc | Saccharide conjugates as delivery agents for oligonucleotides |
US8828956B2 (en) | 2007-12-04 | 2014-09-09 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
JP2019147846A (en) * | 2007-12-04 | 2019-09-05 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8450467B2 (en) | 2007-12-04 | 2013-05-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9867882B2 (en) | 2007-12-04 | 2018-01-16 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2009073809A2 (en) * | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
EP3705125A1 (en) * | 2007-12-04 | 2020-09-09 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
AU2020203054B2 (en) * | 2007-12-04 | 2022-03-03 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9814777B2 (en) | 2007-12-04 | 2017-11-14 | Arbutus Biopharma Corporation | Targeting lipids |
US11666653B2 (en) | 2007-12-04 | 2023-06-06 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
JP2016034974A (en) * | 2007-12-04 | 2016-03-17 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
EP3141265A1 (en) * | 2007-12-04 | 2017-03-15 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2009073809A3 (en) * | 2007-12-04 | 2009-12-30 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US11110174B2 (en) | 2007-12-04 | 2021-09-07 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2009082606A2 (en) * | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
US10806791B2 (en) | 2007-12-04 | 2020-10-20 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9352048B2 (en) | 2007-12-04 | 2016-05-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9370582B2 (en) | 2007-12-04 | 2016-06-21 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9370581B2 (en) | 2007-12-04 | 2016-06-21 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
JP2021080299A (en) * | 2007-12-04 | 2021-05-27 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
US9345780B2 (en) | 2008-04-11 | 2016-05-24 | Tekmira Pharmaceuticals Corporation | Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US9895448B2 (en) | 2008-04-11 | 2018-02-20 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US9957505B2 (en) | 2009-06-01 | 2018-05-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
EP2547769B1 (en) * | 2009-11-25 | 2016-04-06 | ELITechGroup B.V. | Minor groove binder (mgb)-oligonucleotide mirna antagonists |
US8980855B2 (en) | 2009-11-25 | 2015-03-17 | Elitech Holding B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
US9334495B2 (en) | 2009-11-25 | 2016-05-10 | Elitechgroup B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
WO2012030745A1 (en) * | 2010-08-30 | 2012-03-08 | Access Pharmaecuticals, Inc | MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS |
WO2012059612A1 (en) | 2010-11-04 | 2012-05-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivatives of small interfering rnas and use thereof |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US11739332B2 (en) | 2013-06-27 | 2023-08-29 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
US10443058B2 (en) | 2013-06-27 | 2019-10-15 | Roche Innovation Center Copenhagen A/S | Antisense oligomers targeting PCSK9 |
US10385342B2 (en) | 2013-06-27 | 2019-08-20 | Roche Innovation Center Copenhagen A/S | Methods of treatment using antisense oligomers and conjugates targeting PCSK9 |
US10370668B2 (en) | 2013-06-27 | 2019-08-06 | Roche Innovation Center Copenhagen A/S | Manufacture of antisense oligomers and conjugates targeting PCSK9 |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
US10138484B2 (en) | 2014-08-07 | 2018-11-27 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
US9862950B2 (en) | 2014-08-07 | 2018-01-09 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11060091B2 (en) | 2014-11-10 | 2021-07-13 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
WO2016170349A1 (en) * | 2015-04-22 | 2016-10-27 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
US10912790B2 (en) | 2015-04-22 | 2021-02-09 | Mina Therapeutics Limited | C/EBP alpha saRNA compositions and methods of use |
KR20170136542A (en) * | 2015-04-22 | 2017-12-11 | 미나 테라퓨틱스 리미티드 | C / EBP alpha saRNA compositions and methods of use |
US10731157B2 (en) | 2015-08-24 | 2020-08-04 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
US10246709B2 (en) | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
US11174481B2 (en) | 2016-09-02 | 2021-11-16 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11597701B2 (en) | 2017-11-01 | 2023-03-07 | Arrowhead Pharmaceuticals, Inc. | Integrin ligands and uses thereof |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
WO2020069055A1 (en) * | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
WO2020264055A1 (en) * | 2019-06-25 | 2020-12-30 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
WO2023060238A3 (en) * | 2021-10-08 | 2023-05-11 | Regulus Therapeutics Inc. | Methods and compositions for avoiding off-target effects |
Also Published As
Publication number | Publication date |
---|---|
US20100069471A1 (en) | 2010-03-18 |
US20060058266A1 (en) | 2006-03-16 |
AU2005272816A1 (en) | 2006-02-23 |
US9453222B2 (en) | 2016-09-27 |
EP1791567A4 (en) | 2009-12-23 |
WO2006020768A3 (en) | 2007-07-05 |
AU2005272816B2 (en) | 2011-08-11 |
US8017763B2 (en) | 2011-09-13 |
US20150191726A1 (en) | 2015-07-09 |
US8957223B2 (en) | 2015-02-17 |
US8404862B2 (en) | 2013-03-26 |
US7582744B2 (en) | 2009-09-01 |
EP1791567B1 (en) | 2015-07-29 |
EP2990410A1 (en) | 2016-03-02 |
US20090286973A1 (en) | 2009-11-19 |
EP1791567A2 (en) | 2007-06-06 |
US20130184328A1 (en) | 2013-07-18 |
JP5192234B2 (en) | 2013-05-08 |
JP2008509670A (en) | 2008-04-03 |
CA2576233C (en) | 2016-03-15 |
CA2576233A1 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1791567B1 (en) | Chemically modified oligonucleotides | |
US11312957B2 (en) | Modified iRNA agents | |
US10676740B2 (en) | Modified iRNA agents | |
CA2685127A1 (en) | Glycoconjugates of rna interference agents | |
AU2011250733C1 (en) | Chemically modified oligonucleotides | |
AU2013205517B2 (en) | Modified irna agents | |
AU2012202250B2 (en) | Modified iRNA agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2576233 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007525790 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005272816 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005786618 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005272816 Country of ref document: AU Date of ref document: 20050810 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005272816 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005786618 Country of ref document: EP |